

**PRODUCT MONOGRAPH**

**Pr MYLAN-AZITHROMYCIN**  
Azithromycin Tablets  
250 mg  
USP

**Antibacterial Agent**

**Mylan Pharmaceuticals ULC**  
85 Advance Road  
Etobicoke, Ontario  
M8Z 2S6

Date of Revision:  
February 8, 2018

Control number: 213343

## Table of Contents

<b>PART I: HEALTH PROFESSIONAL INFORMATION</b> .....	<b>3</b>
SUMMARY PRODUCT INFORMATION .....	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS .....	5
WARNINGS AND PRECAUTIONS.....	5
ADVERSE REACTIONS.....	9
DRUG INTERACTIONS .....	15
DOSAGE AND ADMINISTRATION.....	21
OVERDOSAGE .....	22
ACTION AND CLINICAL PHARMACOLOGY .....	22
STORAGE AND STABILITY.....	25
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	25
<b>PART II: SCIENTIFIC INFORMATION</b> .....	<b>26</b>
PHARMACEUTICAL INFORMATION.....	26
CLINICAL TRIALS.....	27
DETAILED PHARMACOLOGY .....	30
MICROBIOLOGY .....	33
TOXICOLOGY .....	36
REFERENCES .....	53
<b>PART III: PATIENT MEDICATION INFORMATION</b> .....	<b>58</b>
250 MG TABLETS.....	58

**Pr MYLAN-AZITHROMYCIN**  
Azithromycin Tablets  
250 mg  
USP

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<b>Route of Administration</b>	<b>Dosage Form / Strength</b>	<b>All Non-medicinal Ingredients</b>
Oral	Tablet, 250 mg of azithromycin	Croscarmellose Sodium, Hydroxypropylmethyl Cellulose, Lactose, Magnesium Stearate, Poloxamer 188, Povidone, Silicified Microcrystalline Cellulose, Polyethylene Glycol, Talc and Titanium Dioxide.  250 mg tablets also contain D & C Red No. 27 Aluminum lake, FD & C Blue No. 2 Aluminum Lake, FD & C Red No. 40 Aluminum Lake, FD & C Yellow No. 6 Aluminum Lake

**INDICATIONS AND CLINICAL USE**

**Azithromycin for Oral Administration**

MYLAN-AZITHROMYCIN (azithromycin) are indicated for treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the following diseases and specific conditions. As recommended dosages, durations of therapy, and applicable patient populations vary among these infections, see DOSAGE AND ADMINISTRATION for specific dosing recommendations.

Because some strains are resistant to azithromycin, when applicable, appropriate culture and susceptibility tests should be initiated before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with MYLAN-AZITHROMYCIN may be initiated before results of these tests are known; once the results become available, antibiotic treatment should be adjusted accordingly.

**Adults**

### **Pharyngitis and tonsillitis**

Pharyngitis and tonsillitis caused by *Streptococcus pyogenes* (group A  $\beta$ -hemolytic streptococci) occurring in individuals who cannot use first line therapy.

**NOTE:** Penicillin is the usual drug of choice in the treatment of *Streptococcus pyogenes* pharyngitis, including the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of streptococci from the oropharynx. However, data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present.

### **Acute bacterial exacerbations of chronic obstructive pulmonary disease**

Acute bacterial exacerbations of chronic obstructive pulmonary diseases caused by *Haemophilus influenzae*, *Moraxella catarrhalis*, or *Streptococcus pneumoniae*.

### **Community-acquired pneumonia**

Community-acquired pneumonia caused by *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Mycoplasma pneumoniae* or *Chlamydia pneumoniae* in patients for whom oral therapy is appropriate.

Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia).

### **Uncomplicated skin and skin structure infections**

Uncomplicated skin and skin structure infections caused by *Staphylococcus aureus*, *Streptococcus pyogenes* or *Streptococcus agalactiae*.

### **Genitourinary tract infections**

Urethritis and cervicitis due to *Neisseria gonorrhoeae* or *Chlamydia trachomatis*. Genital ulcer disease in men due to *Haemophilus ducreyi* (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established.

Patients should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed.

### **Prevention of Disseminated *Mycobacterium Avium* Complex (MAC) Disease:**

Azithromycin, taken at a dose of 1200 mg weekly, alone or in combination with rifabutin at its approved dose, is indicated for the prevention of disseminated *Mycobacterium avium* complex (MAC) disease in persons with advanced HIV infections (see CLINICAL TRIALS).

To reduce the development of drug-resistant bacteria and maintain the effectiveness of MYLAN-AZITHROMYCIN and other antibacterial drugs, MYLAN-AZITHROMYCIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

## **CONTRAINDICATIONS**

MYLAN-AZITHROMYCIN are contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin and in those with hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibacterial agent, or to any ingredient in the formulation or component of the container. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING.

## **WARNINGS AND PRECAUTIONS**

### **General**

Serious allergic reactions, including angioedema, anaphylaxis, and dermatological reactions including, Acute Generalized Exanthematous Pustulosis (AGEP), Steven's Johnson syndrome (SJS), toxic epidermolysis, toxic epidermal necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic symptoms (DRESS) have been reported rarely (with rare reports of fatalities), in patients on azithromycin therapy (see CONTRAINDICATIONS). Allergic reactions may occur during and soon after treatment with azithromycin. Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms recurred soon thereafter in some patients without further azithromycin exposure. These patients required prolonged periods of observation and symptomatic treatment. If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.

The use of azithromycin with other drugs may lead to drug-drug interactions. For established or potential drug interactions, see DRUG INTERACTIONS section of the product monograph.

In the absence of data on the metabolism and pharmacokinetics in patients with lysosomal lipid storage diseases (e.g. Tay-Sachs disease, Niemann-Pick disease) the use of azithromycin in these patients is not recommended.

Azithromycin and ergot derivatives should not be co-administered due to the possibility that ergot toxicity may be precipitated by macrolide antibiotics. Acute ergot toxicity is characterized by severe peripheral vasospasm, including ischemia of the extremities, along with dysesthesia and possible central nervous system effects.

As with any antibacterial preparation, observation for signs of superinfection with nonsusceptible organisms, including fungi is recommended.

Due to the lactose content in the tablet coating, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take the tablet formulation.

### **Carcinogenesis and Mutagenesis**

Long term studies in animals have not been performed to evaluate carcinogenic potential. Azithromycin has shown no genotoxic or mutagenic potential in standard laboratory tests (see TOXICOLOGY).

### **Cardiovascular**

Prolonged cardiac repolarisation and QT interval, imparting a risk of developing cardiac arrhythmia and *torsades de pointes*, have been seen in treatment with macrolides including azithromycin (see ADVERSE REACTIONS). Prescribers should consider the risk of QT prolongation which can lead to fatal events when weighing the risks and benefits of azithromycin. Risk factors for *torsades de pointes* include patients:

- With a history of *torsade de pointes*
- With congenital or documented QT prolongation
- Currently receiving treatment with other active substances known to prolong QT interval such as antiarrhythmics of classes IA and III; antipsychotic agents; antidepressants; and fluoroquinolones.
- With electrolyte disturbance, particularly in cases of hypokalaemia and hypomagnesemia
- With clinically relevant bradycardia, cardiac arrhythmia or cardiac insufficiency
- Elderly may be more susceptible to drug-associated effects on the QT interval
- Exposed to higher plasma levels of azithromycin (e.g. receiving intravenous azithromycin, hepatobiliary impaired)

There is information that 'QT Related Adverse Events' may occur in some patients receiving azithromycin. There have been spontaneous reports from post-marketing experience of prolonged QT interval and *torsades de pointes* (see ADVERSE REACTIONS - Post marketing Experience). These include but are not limited to: one AIDS patient dosed at 750 mg to 1 g daily experienced prolonged QT interval and *torsades de pointes*; a patient with previous history of arrhythmias who experienced *torsades de pointes* and subsequent myocardial infarction following a course of azithromycin therapy; and a pediatric case report of prolonged QT interval experienced at a

therapeutic dose of azithromycin which reversed to normal upon discontinuation (see ACTION AND CLINICAL PHARMACOLOGY, Cardiac Electrophysiology).

### **Gastrointestinal**

A higher incidence of gastrointestinal adverse events (8 of 19 subjects) was observed when Azithromycin was administered to a limited number of subjects with GFR<10 mL/min.

#### ***Clostridium difficile*-associated disease**

*Clostridium difficile*-associated disease (CDAD) has been reported with use of many antibacterial agents including azithromycin. CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseudomembranous colitis, toxic megacolon, or perforation of colon subsequent to the administration of any antibacterial agents. CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth of *Clostridium difficile*. *Clostridium difficile* produces toxins A and B which contribute to the development of CDAD. CDAD may cause significant morbidity and mortality. CDAD can be refractory to antimicrobial therapy.

If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against *Clostridium difficile*. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against *Clostridium difficile*. Surgical evaluation should be instituted as clinically indicated; as surgical intervention may be required in certain severe cases (see ADVERSE REACTIONS).

### **Hematologic**

Severe neutropenia (WBC < 1000/mm<sup>3</sup>) may adversely affect the distribution of azithromycin and its transport to the site of infection. Antibacterials with proven efficacy in this population should be used, as outlined by the relevant guidelines for treatment of patients with severe neutropenia. Efficacy and safety of azithromycin have not been studied in patients with severe neutropenia.

### **Hepatic/Biliary/Pancreatic**

Since the liver is the principal route of elimination for azithromycin, the use of oral MYLAN-AZITHROMYCIN preparations should be undertaken with caution in patients with impaired hepatic function. Azithromycin has not been studied in patients with severe hepatic impairment (see ACTION AND CLINICAL PHARMACOLOGY).

### **Hepatotoxicity**

Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death. Rare cases of acute hepatic necrosis requiring liver transplant or causing death have been reported in patients following treatment with oral

azithromycin. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur (see ADVERSE REACTIONS).

### **Musculoskeletal and connective tissue disorders**

#### **Myasthenia gravis**

Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azithromycin therapy. The use of MYLAN-AZITHROMYCIN patients with a known history of myasthenia gravis is not recommended.

### **Renal**

The safety, efficacy and pharmacokinetics of azithromycin in patients with renal impairment have not been established. No dose adjustment is recommended for patients with GFR 10-80 mL/min. Caution should be exercised when azithromycin is administered to patients with GFR <10 mL/min. This precaution is based on a clinical study of azithromycin immediate-release tablets, in which patients with GFR <10 mL/min showed a significant (61%) increase in mean  $C_{max}$  and a significant (35%) increase in systemic exposure to azithromycin, and experienced a high incidence of gastrointestinal adverse events (8 of 19 clinical study subjects). Patients with GFR 10-80 mL/min showed only slightly increased serum azithromycin levels compared to patients with normal renal function.

Due to limited data in subjects with GFR <10 mL/min, caution should be exercised when prescribing oral azithromycin in these patients (see ACTION AND CLINICAL PHARMACOLOGY).

### **Sexual function/Reproduction**

There are no adequate and well-controlled studies in humans. In fertility studies conducted in the rat, reduced pregnancy rates were noted following administration of azithromycin. The predictive value of these data to the response in humans has not been established (see TOXICOLOGY).

### **Susceptibility/Resistance**

#### **Development of drug resistant bacteria**

Prescribing MYLAN-AZITHROMYCIN in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.

### **Special Populations**

#### **Pregnant Women**

There are no adequate and well-controlled studies in pregnant women. MYLAN-AZITHROMYCIN should not be used during pregnancy unless the expected benefit to the mother outweighs any potential risk to the fetus. In animal reproduction studies in mice and rats, at azithromycin doses up to 200 mg/kg/day (moderately maternally toxic), effects were noted in the rat at 200 mg/kg/day, during the prenatal development period (delayed ossification) and



during the postnatal development period (decreased viability, delayed developmental landmarks, differences in performance of learning task). The 200 mg/kg/day dose in mice and rats is approximately 0.5-fold and 1-fold, respectively, the single adult oral dose of 2 g, based on mg/m<sup>2</sup> (body surface area). Pharmacokinetic data from the 200 mg/kg/day dose level in these studies showed that azithromycin crossed the placenta and distributed to fetal tissue at 5 to 9-fold the maternal plasma C<sub>max</sub> of 2 mcg/mL (see TOXICOLOGY).

### **Nursing Women**

Azithromycin has been reported to have been secreted into human breast milk, but there are no adequate and well-controlled clinical studies in nursing women that have characterized the pharmacokinetics of azithromycin excretion into human breast milk. In addition, the safety of azithromycin has not been studied in infants less than 6 months of age. Therefore, MYLAN-AZITHROMYCIN should not be used in the treatment of nursing women unless the expected benefit to the mother outweighs any potential risk to the infant. Because azithromycin may accumulate in breast milk over time with continued MYLAN-AZITHROMYCIN therapy, if the lactating mother is treated with azithromycin, the breast milk should be expressed and discarded during treatment.

### **Geriatrics**

The pharmacokinetics in elderly volunteers (age 65 to 85) were similar to those in younger volunteers (age 18 to 40) for the 5-day oral therapeutic regimen. Dosage adjustment does not appear to be necessary for elderly patients with normal renal and hepatic function receiving treatment with this dosage regimen.

### **Monitoring and Laboratory Tests**

Monitoring of QT/QTc intervals during treatment with MYLAN-AZITHROMYCIN may be considered by the physician as appropriate.

## **ADVERSE REACTIONS**

### **Adverse Drug Reaction Overview**

The majority of side effects observed in controlled clinical trials involving patients (adults and children) treated with oral azithromycin were of a mild and transient nature. Approximately 0.7% of both adult patients (n=3812) and children (n=2878) from the 5-day multiple dose clinical trials discontinued azithromycin therapy because of drug related side effects. Discontinuation rates were slightly higher for PID patients receiving concomitant metronidazole therapy (4%).

In adults given 500 mg/day for 3 days, the discontinuation rate due to treatment-related side effects was 0.4%. In clinical trials in children given 30 mg/kg, orally either as a single dose (n=487) or over 3 days, (n=1729) discontinuation from therapy due to treatment-related side effects was approximately 1%.

Most of the side effects leading to discontinuation in patients on oral therapy were related to the gastrointestinal tract, e.g., nausea, vomiting, diarrhea, along with abdominal pain, rashes.

Potentially serious treatment-related side effects including angioedema and cholestatic jaundice occurred in less than 1% of patients.

### **Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

### **Oral Regimen: Adults**

#### **Multiple-dose Regimens:**

In adult patients, the most common treatment-related side effects in patients receiving the 3 or 5 day oral multiple-dose regimens of azithromycin were related to the gastrointestinal system with diarrhea/loose stools (4-5%), abdominal pain (2-3%), vomiting (1%) and nausea (3-4%).

#### **Treatment-related side effects that occurred with a frequency of 1% or less include:**

<i>Cardiovascular:</i>	hypertension
<i>Gastrointestinal:</i>	dry mouth, esophagitis, gastroenteritis, rectal hemorrhage, cholestatic jaundice
<i>Genitourinary:</i>	mennorrhagia, urinary frequency, vaginitis
<i>Special senses:</i>	conjunctivitis
<i>Nervous system:</i>	dizziness
<i>Allergic:</i>	pruritus

#### **Single 1-gram Dose Regimen:**

In adult patients (n=904), side effects that occurred on the single one-gram dosing regimen of azithromycin with a frequency greater than 1% included diarrhea (6.1%), nausea (4.9%), abdominal pain (4.9%), vomiting (1.7%), vaginitis (1.3%), loose stools (1.2%), and dyspepsia (1.1%).

#### **Single 2-gram Dose Regimen:**

Overall, the most common side effects in patients receiving a single 2-gram dose of azithromycin were related to the gastrointestinal system. Side effects that occurred in patients in this study with a frequency of a 1% or greater included nausea (18.2%), diarrhea/loose stools (13.8%), vomiting (6.7%), abdominal pain (6.7%), vaginitis (2.2%), dyspepsia (1.1%), and dizziness (1.3%). The majority of these complaints were mild in nature.

#### **Prevention of *Mycobacterium Avium* Complex (MAC) Disease:**

Chronic therapy with azithromycin 1200 mg weekly regimen: The nature of side effects seen with the 1200 mg weekly dosing regimen for the prevention of *Mycobacterium avium* complex infection in severely immunocompromised HIV-infected patients were similar to those seen with short-term dosing regimens.

**Incidence<sup>1</sup> (%) of Treatment Related\* Adverse Events\*\* in HIV-Infected Patients Receiving Prophylaxis for Disseminated MAC**

	Study 155		Study 174		
	Placebo (n=91)	Azithromycin 1200 mg weekly (n=89)	Azithromycin 1200 mg weekly (n=233)	Rifabutin 300 mg daily (n=236)	Azithromycin & Rifabutin (n=224)
Mean Duration of Therapy (days)	303.8	402.9	315	296.1	344.4
Discontinuation of Therapy (%)	2.3	8.2	13.5	15.9	22.7
<b>AUTONOMIC NERVOUS SYSTEM</b>					
Mouth Dry	0	0	0	3.0	2.7
<b>CENTRAL NERVOUS SYSTEM</b>					
Dizziness	0	1.1	3.9	1.7	0.4
Headache	0	0	3.0	5.5	4.5
<b>GASTROINTESTINAL</b>					
Diarrhea	15.4	52.8	50.2	19.1	50.9
Loose Stools	6.6	19.1	12.9	3.0	9.4
Abdominal Pain	6.6	27	32.2	12.3	31.7
Dyspepsia	1.1	9	4.7	1.7	1.8
Flatulence	4.4	9	10.7	5.1	5.8
Nausea	11	32.6	27.0	16.5	28.1
Vomiting	1.1	6.7	9.0	3.8	5.8
<b>GENERAL</b>					
Fever	1.1	0	2.1	4.2	4.9
Fatigue	0	2.2	3.9	2.1	3.1
Malaise	0	1.1	0.4	0	2.2
<b>MUSCULOSKELETAL</b>					
Arthralgia	0	0	3.0	4.2	7.1
<b>PSYCHIATRIC</b>					
	1.1	0	2.1	2.1	3.1

	Study 155		Study 174		
	Placebo (n=91)	Azithromycin 1200 mg weekly (n=89)	Azithromycin 1200 mg weekly (n=233)	Rifabutin 300 mg daily (n=236)	Azithromycin & Rifabutin (n=224)
Anorexia					
SKIN & APPENDAGES					
Pruritus	3.3	0	3.9	3.4	7.6
Rash	3.2	3.4	8.1	9.4	11.1
Skin discoloration	0	0	0	2.1	2.2
SPECIAL SENSES					
Tinnitus	4.4	3.4	0.9	1.3	0.9
Hearing Decreased	2.2	1.1	0.9	0.4	0
Taste Perversion	0	0	1.3	2.5	1.3

\* Includes those events considered possibly or probably related to study drug

\*\* >2% adverse event rates for any group

<sup>1</sup> Reflects the occurrence of ≥1 event during the entire treatment period

Side effects related to the gastrointestinal tract were seen more frequently in patients receiving azithromycin than in those receiving placebo or rifabutin. In one of the studies, 86% of diarrheal episodes were mild to moderate in nature with discontinuation of therapy for this reason occurring in only 9/233 (3.8%) of patients.

### **Oral Regimen: Adults**

The most common side effects (greater than 1%) in adult patients who received sequential oral azithromycin in studies of **community-acquired pneumonia** were related to the gastrointestinal system: diarrhea/loose stools (4.3%), nausea (3.9%), abdominal pain (2.7%), and vomiting (1.4%).

In adult women who received sequential oral azithromycin in studies of **pelvic inflammatory disease**, the most common side effects (greater than 1%) were related to the gastrointestinal system. Diarrhea (8.5%) and nausea (6.6%) were most frequently reported, followed by vaginitis (2.8%), abdominal pain (1.9%), anorexia (1.9%), rash and pruritus (1.9%). When azithromycin was co-administered with metronidazole in these studies, a higher proportion of women experienced side effects of nausea (10.3%), abdominal pain (3.7%), vomiting (2.8%) and application site reaction, stomatitis, dizziness, or dyspnea (all at 1.9%).

Side effects that occurred with a frequency of 1% or less included:

*Gastrointestinal:* dyspepsia, flatulence, mucositis, oral moniliasis, and gastritis

*Nervous System:* headache, somnolence

*Allergic:* bronchospasm

*Special Senses:* taste perversion

### **Abnormal Hematologic and Clinical Chemistry Findings**

#### **Oral Therapy:**

##### **Adults:**

Clinically significant abnormalities (irrespective of drug relationship) occurring during the clinical trials in patients were reported as follows:

With an incidence of greater than 1%: decreased hemoglobin, hematocrit, lymphocytes, monocytes, albumin and blood glucose, elevated serum creatine phosphokinase, potassium, ALT (SGPT), GGT and AST (SGOT), BUN, creatinine, blood glucose, platelet count, eosinophils and monocytes.

With an incidence of less than 1%, leukopenia, neutropenia, decreased platelet count, elevated serum alkaline phosphatase, bilirubin, LDH and phosphate.

The majority of subjects with elevated serum creatine also had abnormal values at baseline.

When follow-up was provided, changes in laboratory tests appeared to be reversible.

In multiple-dose clinical trials involving more than 4500 patients, 3 patients discontinued therapy because of treatment-related liver enzyme abnormalities, one for treatment-related elevated transaminases and triglycerides and one because of a renal function abnormality.

#### **Prevention of *Mycobacterium Avium* Complex (MAC) Disease:**

In these immunocompromised patients with advanced HIV infection, it was sometimes necessary to assess laboratory abnormalities developing on study with additional criteria if baseline values were outside the normal range.

#### **Prophylaxis against Disseminated MAC Abnormal Laboratory Values**

Criteria <sup>a</sup>	Study 155		Study 174		
	Placebo (n=88)	Azithromycin 1200 mg weekly (n=89)	Azithromycin 1200 mg weekly (n=208)	Rifabutin 300 mg daily (n=205)	Azithromycin & Rifabutin (n=199)
Hemoglobin <0.8 x LLN <sup>b</sup>	31%	30%	19%	26%	21%
Platelet Count <0.75 x LLN	19%	16%	11%	10%	16%
WBC Count <0.75 x LLN					

Criteria <sup>a</sup>	Study 155		Study 174		
	Placebo (n=88)	Azithromycin 1200 mg weekly (n=89)	Azithromycin 1200 mg weekly (n=208)	Rifabutin 300 mg daily (n=205)	Azithromycin & Rifabutin (n=199)
Neutrophils <0.5 x LLN	48%	49%	60%	53%	60%
<500/mm <sup>3</sup>	16%	28%	23%	20%	29%
AST (SGOT) >2.0 x ULN <sup>c</sup>	6%	13%	5%	6%	8%
>200 U/L	28%	39%	33%	18%	30%
ALT (SGPT) >2.0 x ULN	10%	8%	8%	3%	6%
>250 U/L	24%	34%	31%	15%	27%
	2%	6%	8%	2%	6%

<sup>a</sup> secondary criteria also applied if baseline abnormal, as follows: Hemoglobin, 10% decrease; Platelet, 20% decrease; WBC count, 25% decrease; Neutrophils, 50% decrease; AST (SGOT), 50% increase; ALT (SGPT), 50% increase.

<sup>b</sup> lower limit of normal

<sup>c</sup> upper limit of normal

In a phase I drug interaction study performed in normal volunteers, 1 of 6 subjects given the combination of azithromycin and rifabutin, 1 of 7 given rifabutin alone and 0 of 6 given azithromycin alone developed a clinically significant neutropenia (<500 cells/mm<sup>3</sup>).

### **Post-Market Adverse Drug Reactions**

The following adverse experiences have been reported in patients under conditions (e.g., open trials, marketing experience) where a causal relationship is uncertain or in patients treated with significantly higher than the recommended doses for prolonged periods:

In addition, because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency is not always possible.

*Allergic:* Arthralgia, edema, anaphylaxis (with rare reports of fatalities) (see WARNINGS AND PRECAUTIONS), serum sickness, urticaria, vasculitis, angioedema, pruritus;

*Blood and the lymphatic system disorders:* Agranulocytosis, haemolytic anaemia, thrombocytopenia

*Cardiovascular:* Cardiac arrhythmias (including ventricular tachycardia), palpitations, hypotension. There have been rare reports of QT prolongation and *torsades de pointes* in patients receiving therapeutic doses of azithromycin, including a pediatric case report of QT interval prolongation which reversed to normal upon discontinuation (see WARNINGS AND PRECAUTIONS);

*Gastrointestinal:* Anorexia, constipation, hypoglycaemia, dehydration, vomiting/diarrhea rarely resulting in dehydration, pancreatitis, pseudomembranous colitis, rare reports of tongue discoloration, pyloric stenosis / infantile hypertrophic pyloric stenosis (IHPS);

*General:* Asthenia, paresthesia, fatigue, muscle pain;

*Genitourinary:* Interstitial nephritis, acute renal failure, nephrotic syndrome, vaginitis;

*Liver/Biliary:* Hepatitis fulminant. Abnormal liver function including drug-induced hepatitis and cholestatic jaundice has been reported. There have also been rare cases of hepatic necrosis and hepatic failure, which have resulted in death (see WARNINGS AND PRECAUTIONS);

*Musculoskeletal and connective tissue disorders:*

Myasthenia gravis

*Nervous System:* Dizziness, hyperactivity, hypoesthesia, seizure, convulsions and syncope;

*Psychiatric*

*Disorders:* Aggressive reaction, anxiety, nervousness, agitation, delirium, hallucinations

*Skin/Appendages:* Serious skin reactions including erythema multiforme, exfoliative dermatitis, Acute Generalized Exanthematous Pustulosis (AGEP), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) (see WARNINGS and PRECAUTIONS).;

*Special Senses:* Hearing disturbances including hearing loss, hearing impaired, deafness and/or tinnitus, vertigo, taste/ smell perversion and/or loss, abnormal vision.

## **DRUG INTERACTIONS**

### **Overview**

Caution is warranted when azithromycin is administered to a patient with a history of a significant cardiac repolarization disorder or who is taking other medicinal products that cause a prolonged QT interval (see WARNINGS AND PRECAUTIONS, Cardiovascular and ADVERSE REACTIONS, Post-Marketing Experience).

Azithromycin does not interact significantly with the hepatic cytochrome P450 system. It is not believed to undergo the cytochrome P450-related drug interactions seen with erythromycin and other macrolides. Hepatic cytochrome P450 induction or inhibition via cytochrome metabolite complex does not occur with azithromycin.

Concomitant administration of azithromycin with P-glycoprotein substrates may result in increased serum levels of P-glycoprotein substrates. Concomitant administration of P-glycoprotein inhibitors with azithromycin sustained-release form had minimal effect on the pharmacokinetics of azithromycin.

### **Drug-Drug Interactions**

#### **Established or Potential Drug-Drug Interactions**

<b>Proper name</b>	<b>Ref</b>	<b>Effect</b>	<b>Clinical comment</b>
<b>Antacids</b> Aluminum and magnesium containing antacids	CT	Reduce the peak serum levels but not the extent of azithromycin absorption.	Azithromycin and these drugs should not be taken simultaneously.



<b>Carbamazepine</b>	CT	In a pharmacokinetic interaction study in healthy volunteers, no significant effect was observed on the plasma levels of carbamazepine or its active metabolite in patients receiving concomitant azithromycin.	
<b>Cetirizine</b>	CT	In healthy male volunteers, co-administration of a 5-day regimen of azithromycin with cetirizine 20 mg at steady-state resulted in no pharmacokinetic interaction and no significant changes in the QT interval.	
<b>Cimetidine</b>	CT	Administration of a single dose of cimetidine (800 mg) two hours prior to azithromycin had no effect on azithromycin absorption or on azithromycin pharmacokinetics.	
<b>Coumarin-Type Oral Anticoagulants</b>	CT	In a pharmacokinetic interaction study of 22 healthy men, a 5-day course of azithromycin did not affect the prothrombin time from a subsequently administered single 15 mg dose of warfarin,  Spontaneous post-marketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral anticoagulants.	Prothrombin times should be carefully monitored while patients are receiving azithromycin and concomitantly-administered oral anticoagulants.
<b>Cyclosporine</b>	CT	In a pharmacokinetic study with healthy volunteers that were administered a 500 mg/day oral dose of azithromycin for 3 days and were then administered a single 10 mg/kg oral dose of cyclosporine, the resulting cyclosporine $C_{max}$ and $AUC_{0-5}$ were found to be significantly elevated.	Caution should be exercised before considering concurrent administration of these drugs. If coadministration of these drugs is necessary, cyclosporine levels should be monitored and the dose adjusted accordingly.
<b>Didanosine</b>	CT	Daily doses of 1200 mg azithromycin had no effect on the pharmacokinetics of didanosine.	
<b>Efavirenz</b>	CT	Efavirenz, when administered at a dose of 400 mg for seven days produced a 22% increase in the $C_{max}$ of azithromycin administered as a 600 mg single dose. AUC was not affected.  Administration of a single 600 mg dose of azithromycin immediate-release had no effect on the pharmacokinetics of efavirenz given at 400 mg doses for seven days.	

<b>Fluconazole</b>	CT	<p>A single dose of 1200 mg azithromycin immediate-release did not alter the pharmacokinetics of a single 800 mg oral dose of fluconazole.</p> <p>Total exposure and half-life of 1200 mg azithromycin were unchanged and <math>C_{max}</math> had a clinically insignificant decrease (18%) by coadministration with 800 mg fluconazole.</p>	
<b>HMG-CoA Reductase Inhibitors</b>	CT	<p>In healthy volunteers, co-administration of atorvastatin (10 mg daily) and azithromycin immediate-release (500 mg daily) did not alter plasma concentrations of atorvastatin (based on HMG CoA-reductase inhibition assay).</p> <p>However, post-marketing cases of rhabdomyolysis in patients receiving azithromycin with statins have been reported.</p>	
<b>Indinavir</b>	CT	<p>A single dose of 1200 mg azithromycin immediate-release had no significant effect on the pharmacokinetics of indinavir (800 mg indinavir three times daily for 5 days).</p>	
<b>Midazolam</b>	CT	<p>In healthy volunteers (N=12), co-administration of azithromycin immediate-release 500 mg/day for 3 days did not cause clinically significant changes in the pharmacokinetics and pharmacodynamics of a single 15 mg dose of midazolam.</p>	
<b>Nelfinavir</b>	CT	<p>Coadministration of a single dose of 1200 mg azithromycin immediate-release with steady-state nelfinavir (750 mg three times daily) produced an approximately 16% decrease in mean <math>AUC_{0-8}</math> of nelfinavir and its M8 metabolite. <math>C_{max}</math> was not affected.</p> <p>Coadministration of nelfinavir (750 mg three times daily) at steady-state with a single dose of 1200 mg azithromycin immediate-release increased the mean <math>AUC_{0-\infty}</math> of azithromycin by 113% and mean <math>C_{max}</math> by 136%.</p>	<p>Dose adjustment of azithromycin is not recommended. However, close monitoring for known side effects of azithromycin, when administered in conjunction with nelfinavir, is warranted.</p>
<b>P-glycoprotein inhibitors</b>	CT	<p>Co-administration of P-glycoprotein inhibitors (Vitamin E, Poloxamer 407, or Poloxamer 124) with azithromycin sustained release form (1 gram dose) had minimal effect on the pharmacokinetics of azithromycin.</p>	

<b>Rifabutin</b>	CT	Co-administration of azithromycin and rifabutin did not affect the serum concentrations of either drug. Neutropenia was observed in subjects receiving concomitant treatment with azithromycin and rifabutin.	Neutropenia has been associated with the use of rifabutin, but it has not been established if concomitantly-administered azithromycin potentiates that effect (see ADVERSE REACTIONS).
<b>Sildenafil</b>	CT	In normal healthy male volunteers, there was no evidence of a statistically significant effect of azithromycin immediate-release (500 mg daily for 3 days) on the AUC, C <sub>max</sub> , T <sub>max</sub> , elimination rate constant or subsequent half-life of sildenafil or its principal circulating metabolite.	
<b>Theophylline</b>	CT	Concurrent use of macrolides and theophylline has been associated with increases in the serum concentrations of theophylline. Azithromycin did not affect the pharmacokinetics of theophylline administered either as a single intravenous infusion or multiple oral doses at a recommended dose of 300 mg every 12 hours.  There is one post-marketing report of supraventricular tachycardia associated with an elevated theophylline serum level that developed soon after initiation of treatment with azithromycin.	Until further data are available, prudent medical practice dictates careful monitoring of plasma theophylline levels in patients receiving azithromycin and theophylline concomitantly.
<b>Trimethoprim / Sulfamethoxazole</b>	CT	Co-administration of trimethoprim/sulfamethoxazole (160 mg/800 mg) for 7 days with azithromycin immediate-release 1200 mg on Day 7 had no significant effect on peak concentrations, total exposure or urinary excretion of either trimethoprim or sulfamethoxazole. Azithromycin serum concentrations were similar to those seen in other studies.	
<b>Zidovudine</b>	CT	Single 1 g doses and multiple 1200 mg or 600 mg doses of azithromycin did not affect the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite. However, administration of azithromycin increased the concentrations of phosphorylated zidovudine, the clinically active metabolite in peripheral blood mononuclear cells.	

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical; UNK = Unknown

### **Concomitant Therapy**

The following drug interactions have not been reported in clinical trials with azithromycin and no specific drug interaction studies have been performed to evaluate potential drug-drug interactions. Nonetheless, they have been observed with macrolide products, and there have been rare spontaneously reported cases with azithromycin and some of these drugs, in post marketing experience. Until further data are developed regarding drug interactions, when MYLAN-AZITHROMYCIN and these drugs are used concomitantly, careful monitoring of patients is advised both during and for a short period following therapy:

### **Antihistamines**

Prolongation of QT intervals, palpitations or cardiac arrhythmias has been reported with concomitant administration of azithromycin and astemizole or terfenadine.

### **Cisapride, Hexobarbital, Phenytoin**

Increased serum levels of hexobarbital, cisapride or phenytoin have been reported.

### **Digoxin / P-glycoprotein substrates**

Concomitant administration of some macrolide antibiotics with P-glycoprotein substrates, including digoxin, has been reported to result in increased serum levels of the P-glycoprotein substrate. Therefore, if azithromycin and P-gp substrates such as digoxin are administered concomitantly, the possibility of elevated serum digoxin concentrations should be considered. Clinical monitoring and possibly serum digoxin levels, during treatment with azithromycin and after its discontinuation are necessary.

### **Disopyramide**

Azithromycin may increase the pharmacologic effect of disopyramide.

### **Ergot (ergotamine or dihydroergotamine)**

Azithromycin and ergot derivatives should not be co-administered due to the possibility that ergot toxicity may be precipitated by some macrolide antibiotics. Acute ergot toxicity is characterized by severe peripheral vasospasm including ischemia of the extremities, along with dysesthesia and possible central nervous system effects.

### **Gentamicin**

No data are available on the concomitant clinical use of azithromycin and gentamicin or other amphiphilic drugs which have been reported to alter intracellular lipid metabolism.

### **Triazolam**

Azithromycin may decrease the clearance of triazolam and increase the pharmacologic effect of triazolam.

### **Drug-Food Interactions**

Azithromycin tablets and powder for oral suspension can be taken with or without food.

### **Drug-Herb Interactions**

Interactions with herbal products have not been established.

## **Drug-Laboratory Interactions**

Interactions with laboratory tests have not been established.

## **DOSAGE AND ADMINISTRATION**

### **Dosing Considerations**

#### **General**

##### **Hepatic Impairment**

No dose adjustment of MYLAN-AZITHROMYCIN is recommended for patients with mild to moderate hepatic impairment. Azithromycin has not been studied in patients with severe hepatic impairment. Since the liver is the principal route of elimination for azithromycin, the use of oral MYLAN-AZITHROMYCIN preparations should be undertaken with caution in patients with impaired hepatic function (see WARNINGS AND PRECAUTIONS and ACTION AND CLINICAL PHARMACOLOGY).

##### **Renal Impairment**

No dosage adjustment of oral MYLAN-AZITHROMYCIN preparations is recommended for subjects with mild to moderate (GFR 10-80 mL/min) renal impairment. The mean AUC<sub>0-120</sub> increased 35% in subjects with GFR <10 mL/min compared to subjects with normal renal function. Caution should be exercised when azithromycin is administered to subjects with severe renal impairment. No studies have been conducted in patients requiring hemodialysis (see ACTION AND CLINICAL PHARMACOLOGY and WARNINGS AND PRECAUTIONS).

### **Recommended Dose and Dosage Adjustment**

#### **MYLAN-AZITHROMYCIN FOR ORAL THERAPY**

##### **Adults**

##### **DOSING in relation to FOOD:**

**Tablets:** MYLAN-AZITHROMYCIN Tablets can be taken with or without food.

##### **Upper and Lower Respiratory Infections/Skin and Skin Structure Infections:**

The recommended dose of MYLAN-AZITHROMYCIN for individuals 16 years of age or older in the treatment of mild to moderate acute bacterial exacerbations of chronic obstructive pulmonary disease due to the indicated organisms is: either 500 mg per day for 3 days or 500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5 for a total dose of 1.5 grams.

The recommended dose of MYLAN-AZITHROMYCIN for the treatment of community-acquired pneumonia of mild severity, uncomplicated skin and skin structure infections, and for pharyngitis/tonsillitis (as second-line therapy) due to the indicated organisms is: 500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5 for a total dose of 1.5 grams.

**Genitourinary Infections:**

The recommended dose of MYLAN-AZITHROMYCIN for the treatment of genital ulcer disease due to *Haemophilus ducreyi* (chancroid) and non-gonococcal urethritis and cervicitis due to *C. trachomatis* is: a single 1 gram (1000 mg) oral dose of MYLAN-AZITHROMYCIN. This dose can be administered as four 250 mg tablets.

The recommended dose of MYLAN-AZITHROMYCIN for the treatment of urethritis and cervicitis due to *Neisseria gonorrhoeae* is: a single 2 gram (2000 mg) dose of MYLAN-AZITHROMYCIN. This dose can be administered as eight 250 mg tablets.

**For Prevention of Disseminated *Mycobacterium Avium* Complex (MAC) Disease:**

The recommended dose of MYLAN-AZITHROMYCIN for the prevention of disseminated *Mycobacterium avium* complex (MAC) disease is 1200 mg (two 600 mg tablets) taken once weekly. This dose of MYLAN-AZITHROMYCIN may be continued with the approved dosage regimen of rifabutin.

**OVERDOSAGE**

Activated charcoal may be administered to aid in the removal of unabsorbed drug. General supportive measures are recommended.

Ototoxicity and gastrointestinal adverse events may occur with an overdose of azithromycin.

Up to 15 grams cumulative dose of azithromycin over 10 days has been administered in clinical trials without apparent adverse effect.

Adverse events experienced in higher than recommended doses were similar to those seen at normal doses.

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.

**ACTION AND CLINICAL PHARMACOLOGY**

**Mechanism of Action**

Azithromycin, a macrolide antibiotic of the azalide subclass, exerts its antibacterial action by binding to the 23S rRNA of the 50s ribosomal subunits of susceptible bacteria. It blocks protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by

inhibiting the assembly of the 50S ribosomal subunit.

## **Pharmacodynamics**

### **Cardiac Electrophysiology:**

QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial. A total of 119 healthy subjects were enrolled (mean age of 35.5 years; range 18-55 years), of which 116 subjects (97 males) completed the study and were included in the analysis. Subjects were randomized to one of 5 treatments and received orally once daily for 3 days: placebo, chloroquine 600 mg base only, or chloroquine 600 mg base in combination with azithromycin 500 mg, 1000 mg, and 1500 mg. On Day 3, the azithromycin mean (%CV) plasma C<sub>max</sub> values for the 500, 1000 and 1500 mg azithromycin dose regimens were 0.536 (33), 0.957 (31), and 1.54 (28) mcg/mL, respectively. Co-administration of azithromycin increased the QTc interval in a dose- and concentration-dependent manner. In comparison to chloroquine alone, the day 3 maximum mean (90% upper confidence bound) increases in QTcF were 5 (10) ms, 7 (12) ms and 9 (14) ms with the co-administration of 500 mg, 1000 mg and 1500 mg azithromycin, respectively.

## **Pharmacokinetics**

No data exist in humans in regard to the extent of accumulation, duration of exposure, metabolism or excretory mechanisms of azithromycin in neural tissue such as the retina and the cochlea.

### **Adult Pharmacokinetics**

Plasma concentrations of azithromycin decline in a polyphasic pattern, resulting in an average terminal half-life of 68 hours. The prolonged half-life is likely due to extensive uptake and subsequent release of drug from tissues. Over the dose range of 250 to 1000 mg orally, the serum concentrations are related to dose.

In adults, the following pharmacokinetic data have been reported:

<b>DOSE/DOSAGE FORM</b>	<b>Subjects</b>	<b>C<sub>max</sub> (mcg/mL)</b>	<b>T<sub>max</sub> (hr)</b>	<b>AUC (mc.hr/mL)</b>	<b>T<sub>1/2</sub> (hr)</b>
500 mg/250 mg tablet	12; fasted	0.34	2.1	2.49 <sup>a</sup>	-
500 mg/250 mg tablet	12; fed	0.41	2.3	2.40 <sup>a</sup>	-
1200 mg/600 mg tablet	12; fasted	0.66	2.5	6.8 <sup>b</sup>	40

<sup>a</sup> 0-48 hr; <sup>b</sup> 0-last

### **Absorption**

Following oral administration, azithromycin is rapidly absorbed (T<sub>max</sub> = 2-3 hours) and distributed widely throughout the body, (see DETAILED PHARMACOLOGY).

The absolute bioavailability is approximately 37%.

Food does not affect the absorption of azithromycin in the tablet dosage form. Azithromycin tablets can be taken with or without food.

### **Distribution**

The serum protein binding of azithromycin is concentration dependent, decreasing from 51% at 0.02 mcg/mL to 7% at 2.0 mcg/mL. Following oral administration, azithromycin is widely distributed throughout the body with a steady-state apparent volume of distribution of 31.1 L/kg.

Rapid movement of azithromycin from blood into tissue results in significantly higher azithromycin concentrations in tissue than in plasma (up to 50 times the maximum observed concentration in plasma), (see DETAILED PHARMACOLOGY).

The long tissue half-life and large volume of distribution result from intracytoplasmic uptake and storage in lysosomal phospholipid complexes.

### **Metabolism**

The majority of systemically available azithromycin is excreted unchanged in the bile. Metabolites of azithromycin were identified in bile but have not been studied further, (see DETAILED PHARMACOLOGY).

### **Excretion**

Biliary excretion of azithromycin, predominantly as unchanged drug, is a main route of elimination. Over the course of a week, approximately 6% of the administered dose appears as unchanged drug in the urine, (see DETAILED PHARMACOLOGY).

### **Special Populations and Conditions**

#### **Geriatrics**

When studied in healthy elderly subjects from age 65 to 85 years, the pharmacokinetic parameters of azithromycin in elderly men were similar to those in young adults; however, in elderly women, although higher peak concentrations (increased by 30 to 50%) were observed, no significant accumulation occurred.

#### **Gender**

There are no significant differences in the disposition of immediate-release azithromycin between male and female subjects. No dosage adjustment is recommended based on gender.

#### **Hepatic Insufficiency**

In patients with mild to moderate hepatic impairment, there is no evidence of a marked change in serum pharmacokinetics of oral azithromycin compared to those with normal hepatic function. In these patients urinary recovery of azithromycin appears to increase. Hence no dose adjustment is recommended for patients with mild to moderate hepatic impairment. Azithromycin has not been studied in patients with severe hepatic impairment.

#### **Renal Insufficiency**

Azithromycin pharmacokinetics were investigated in 42 adults (21 to 85 years of age) with varying degrees of renal impairment. Following the oral administration of a single 1,000 mg dose of



azithromycin, mean  $C_{max}$  and  $AUC_{0-120}$  increased by 5.1% and 4.2%, respectively in subjects with mild to moderate renal impairment (GFR 10 to 80 mL/min) compared to subjects with normal renal function (GFR >80 mL/min). The mean  $C_{max}$  and  $AUC_{0-120}$  increased 61% and 35%, respectively in subjects with severe renal impairment (GFR <10 mL/min) compared to subjects with normal renal function (GFR >80 mL/min).

## **STORAGE AND STABILITY**

### **Tablets:**

Store between 15°C and 30°C.

## **DOSAGE FORMS, COMPOSITION AND PACKAGING**

### **Dosage Forms**

#### **Tablets:**

**250 mg:** Each dark pink, coated, modified capsule-shaped tablet engraved with a “G” logo on one side and “250” on the other side, contains 250 mg of azithromycin, and the following nonmedicinal ingredients: Croscarmellose sodium, D&C Red No. 27, FD&C Blue No. 2, FD&C Red No. 40, FD&C Yellow No.6, Hydroxypropylmethyl Cellulose, Lactose, Magnesium Stearate, Poloxamer 188, Povidone, Silicified Microcrystalline Cellulose, Polyethylene Glycol, Talc and Titanium Dioxide.

### **Packaging**

#### **Tablets:**


MYLAN-AZITHROMYCIN 250 mg Film-Coated Tablets is available in HDPE bottles of 30 and Blister Packs of 6 tablets.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION

#### Drug Substance

Proper name:	Azithromycin Dihydrate
Chemical name:	9-deoxo-9 $\alpha$ -aza-9 $\alpha$ -methyl-9 $\alpha$ -homoerythromycin A dihydrate
Molecular formula and molecular mass:	C <sub>38</sub> H <sub>72</sub> N <sub>2</sub> O <sub>12</sub> · 2H <sub>2</sub> O, 785.0 g/mol
Structural formula:	



#### Physicochemical properties:

Description:	Azithromycin dihydrate is a white to off-white crystalline powder of uniform appearance. The aqueous solubility at pH 7.4 at 37°C is 39 mg/mL. The powder is non-hygroscopic.
pKa	8.48
Melting point:	125°C

## CLINICAL TRIALS

### Comparative Bioavailability Studies

A comparative bioavailability study of MYLAN-AZITHROMYCIN 600 mg tablets (Pharmascience Inc, Canada) was performed versus ZITHROMAX<sup>®</sup> 600 mg tablets (Pfizer Canada Inc). Pharmacokinetic and bioavailability data were measured and the results are summarized in the following table:

**SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA**

<b>Azithromycin</b> ( 400 mg dose - 1 x 10 mL) From measured data Geometric Mean Arithmetic Mean (CV %)				
<b>Parameter<sup>&amp;</sup></b>	<b>AZITHROMYCIN<sup>**</sup></b>	<b>ZITHROMAX<sup>®</sup>***</b>	<b>% Ratio of Geometric Means</b>	<b>Confidence Interval 90%</b>
AUC <sub>0-72h</sub> (ng-h/mL)	2585.52 2662.74 (28.04)	2510.70 2622.83 (30.57)	102.98	94.63-1
C <sub>MAX</sub> (ng/mL)	330.56 345.80 (27.76)	336.36 (350.43 (28.71)	98.27	85.57-1
T <sub>MAX</sub> <sup>*</sup> (h)	2.55 (40.81)	2.34 (39.76)	---	---

<sup>&</sup> Due to the nature of the active ingredient (long half-life) and the design of the study, AUC<sub>1</sub> and T<sub>1/2</sub> could not be accurately estimated; therefore, they are not reported.

<sup>\*</sup>expressed as arithmetic mean (CV %) only.

<sup>\*\*</sup> MYLAN-AZITHROMYCIN, Pharmascience Inc, Canada

<sup>\*\*\*</sup>ZITHROMAX<sup>®</sup> is manufactured by Pfizer Canada Inc. and purchased in Canada.

## Study results

From the perspective of evaluating clinical trials because of the extended half-life of azithromycin, days 11-14 (10-13 days after completion of the one-day regimen, 8-11 days after completion of the three-day regimen or 6-9 days after completion of the five-day regimen) were considered on-therapy evaluations and are provided for clinical guidance. Day 21-30 evaluations were considered the primary test of cure endpoint. For patients with community-acquired pneumonia, Days 15-19 were considered as on-therapy evaluations. Days 28-42 were the cure endpoint.

## Adult Patients

### Acute Bacterial Exacerbations of Chronic Bronchitis

#### Efficacy using azithromycin 500 mg over 3 days


In a randomized, double-blind controlled clinical trial of acute exacerbation of chronic bronchitis (AECB) in 404 adult patients; azithromycin (500 mg once daily for 3 days) was compared with clarithromycin (500 mg twice daily for 10 days). The primary endpoint of this trial was the clinical cure rate at Day 21-24. For the 377 patients analyzed in the MITT analysis at the Day 21-24 visit, the clinical cure rate for 3 days of azithromycin was 87% (162/186) compared to 85% (162/191) for 10 days of clarithromycin (95% CI for azithromycin-clarithromycin cure rate = -5.3, 9.8).

The following outcomes were the clinical cure rates at the Day 21-24 visit for the bacteriologically evaluable patients by pathogen:

Clinical Outcome by Baseline Pathogen		
Pathogen	Azithromycin (3 days)	Clarithromycin (10 days)
<i>S. pneumoniae</i>	29/32 (91%)	21/27 (78%)
<i>H. influenzae</i>	12/14 (86%)	14/16 (88%)
<i>M. catarrhalis</i>	11/12 (92%)	12/15 (80%)

### Clinical Trials: In patients with advanced HIV infection for the prevention of disseminated *Mycobacterium avium* complex (MAC) disease (see INDICATIONS AND CLINICAL USE)

Two randomized, double-blind clinical trials were performed in patients with CD4 counts <100 cells/mcL. The first study compared azithromycin (1200 mg once weekly) to placebo and enrolled 182 patients with a mean CD4 count of 35 cells/mcL. The second study randomized 723 patients to azithromycin (1200 mg once weekly), rifabutin (300 mg daily) or the combination of both. The mean CD4 count was 51 cells/mcL. Endpoints included disseminated MAC disease, the incidence of clinically significant disseminated MAC disease and discontinuations from therapy for drug-related side effects.



### MAC Bacteremia

In the first study, in the intent-to-treat analysis comparing azithromycin to placebo, patients randomized to azithromycin were one-half as likely to develop MAC as those who received placebo ( $p=0.004$ ). The one year cumulative incidence rate of disseminated MAC disease was 8.25% on azithromycin and 20.22% on placebo.

In the second study, in the intent-to-treat analysis comparing azithromycin, rifabutin and the combination of azithromycin/rifabutin, the risk of developing MAC bacteremia for patients assigned to azithromycin was also reduced by one-half relative to rifabutin ( $p=.005$ ). Patients on the combination of azithromycin and rifabutin experienced a risk reduction of approximately two-thirds compared to rifabutin alone ( $p<0.001$ ). The one year cumulative incidence rate of MAC infection was 7.62% on azithromycin, 15.25% on rifabutin and 2.75% on the combination.

In the placebo-controlled first study, all MAC isolates recovered within 30 days of the last dose of drug from patients randomized to azithromycin were sensitive to azithromycin. In the second study, 2 of 23 (8.7%) isolates received from patients randomized to azithromycin were resistant to azithromycin while none of the isolates received from patients randomized to rifabutin were resistant to azithromycin ( $p=0.14$ ). None of the isolates recovered from patients randomized to the combination of azithromycin and rifabutin were resistant to azithromycin.

### Clinically Significant Disseminated MAC Disease

In association with the decreased incidence of bacteremia, patients in the groups randomized to either azithromycin alone or azithromycin in combination with rifabutin showed reductions in the signs and symptoms of disseminated MAC disease, including fever or night sweats, weight loss and anemia.

### Discontinuations from Therapy for Drug-Related Side Effects

In the first study, discontinuations for drug-related toxicity occurred in 8.2% of subjects treated with azithromycin and 2.3% of those given placebo (p=0.121). In the second study, more subjects discontinued from the combination of azithromycin and rifabutin (22.7%) than from azithromycin alone (13.5%; p=0.026) or rifabutin alone (15.9%).

### DETAILED PHARMACOLOGY

Following oral administration, azithromycin is rapidly absorbed ( $T_{max}$ =2-3 hours) and distributed widely throughout the body. Rapid movement of azithromycin from blood into tissue results in significantly higher azithromycin concentrations in tissue than in plasma (up to 50 times the maximum observed concentration in plasma). The absolute bioavailability is approximately 37%.

#### Adults

Following administration of a 500 mg oral dose, the maximum serum concentration ( $C_{max}$ ) is 0.4 mcg/mL and is attained 2-3 hours after dosing with areas under the curve of 2.6 mcg.hr/mL ( $AUC_{0-24}$ ) and 3.7 mcg.hr/mL ( $AUC_{0-48}$ ) and trough levels of 0.05 mcg/mL. These oral values are approximately 38%, 83% and 52% of the values observed following a single 500 mg IV 3-hour infusion:  $C_{max}$  1.08 mcg/mL, trough level 0.06 mcg/mL, and  $AUC_{24}$  5.0 mcg.hr/mL. Thus, plasma concentrations are higher following the intravenous regimen throughout the 24-hour interval. Also refer to tabulated pharmacokinetic data reported in adults under ACTION AND CLINICAL PHARMACOLOGY, Adult Pharmacokinetics section. When studied in healthy elderly subjects from age 65 to 85 years, the pharmacokinetic parameters of azithromycin in elderly men were similar to those in young adults; however, in elderly women, although higher peak concentrations (increased by 30 to 50%) were observed, no significant accumulation occurred.

The pharmacokinetic parameters of azithromycin in plasma, after a loading dose of 500 mg on day 1 followed by 250 mg q.d. on days 2 through 5 in healthy young adults (age 18-40 years old) are presented in the following table:

**Pharmacokinetic Parameters (Mean) in Adult Subjects (Total n=12) on Days 1 and 5\***

	Day 1	Day 5
$C_{max}$ (mcg/mL)	0.41	0.24
$T_{max}$ (h)	2.5	3.2
$AUC_{0-24}$ (mcg·h/mL)	2.6	2.1
$C_{min}$ (mcg/mL)	0.05	0.05
Urinary Excret. (% dose)	4.5	6.5

\* 2 x 250 mg on Day 1 followed by one 250 mg on Days 2 through 5

In this study, there was no significant difference in the disposition of azithromycin between male and female subjects. Plasma concentrations of azithromycin declined in a polyphasic pattern resulting in an average terminal half-life of 68 hours. With this regimen,  $C_{min}$  and  $C_{max}$  remained essentially unchanged from day 2 through day 5 of therapy. However, without a loading dose, azithromycin  $C_{min}$  levels required 5 to 7 days to reach steady-state.

In a two-way crossover study, 12 adult normal volunteers (6 males; 6 females) received 1500 mg of azithromycin, administered in single daily doses over either 5 days (two 250 mg tablets on day 1, followed by one 250 mg tablet on days 2-5) or 3 days (500 mg per day). Mean peak serum concentrations were similar on day 1 for both regimens and slightly higher on days 2 and 3 for the 3-day regimen, suggesting that there is minimal serum accumulation of azithromycin on days 2 and 3 of the 3-day regimen.

Pharmacokinetic Parameter (mean)	3-Day Regimen			5-Day Regimen	
	Day 1	Day 2	Day 3	Day 1	Day 5
$C_{max}$ (serum, mcg/mL)	0.310	0.446	0.383	0.290	0.182
Serum $AUC_{0-\infty}$ (mcg.hr/mL)	15.2			14.5	
Kel ( $hr^{-1}$ )	0.0101			0.0105	
Serum $T_{1/2}$	68.6 hr			66.0 hr	

Mean  $AUC_{0-\infty}$  for both regimens were similar, with a ratio of  $AUC_{0-\infty}$  (3-day)/ $AUC_{0-\infty}$  (5-day) of 105% (90% CI=93, 120). Serum concentrations of azithromycin declined in a polyphasic pattern resulting in average terminal half-life of 68.6 hours for the 3-day regimen and about 66 hours for the 5-day regimen.

Median azithromycin exposure ( $AUC_{0-288}$ ) in mononuclear (MN) and polymorphonuclear (PMN) leukocytes following either the 5-day or 3-day regimen was more than 1000-fold and 800-fold greater than in serum, respectively. Administration of the same total dose with either the 5-day or 3-day regimen may be expected to provide comparable concentrations of azithromycin with MN and PMN leukocytes.

The table below compares pharmacokinetic parameters following single oral doses of 500 mg azithromycin with those obtained after a single 500 mg IV 3-hour infusion.

**Pharmacokinetic parameters in adults after oral  
and intravenous administration of 500 mg azithromycin**

	<b>C<sub>max</sub> (mcg/mL)</b>	<b>trough level (mcg/mL)</b>	<b>AUC<sub>0-24</sub> (mcg. h/mL)</b>
500 mg single oral dose	0.41	0.05	2.5
500 mg IV infusion over 3 hours	1.08	0.06	5

Thus, plasma concentrations are higher following the intravenous regimen throughout the 24-hour interval. Although tissue levels have not been obtained following intravenous infusions of azithromycin, these data suggest that they would be substantially greater than those observed following oral administration.

After oral administration, serum concentrations of azithromycin decline in a polyphasic pattern, resulting in an average terminal half-life of 68 hours.

The high values for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues. The tissue (or fluid) to plasma concentration ratios for key sites of infection are shown in the following table:

<b>Azithromycin Concentrations Following the Recommended Clinical Dosage Regimen of 500 mg (2 x 250 mg) on Day 1 Followed by 250 mg Daily for Four Additional Days</b>				
<b>Tissue or Fluid</b>	<b>Sample Time after Final Dose (hrs)</b>	<b>Tissue or Fluid mcg/g or mcg/mL</b>	<b>Plasma/Serum mcg/mL</b>	<b>Concentration Ratio</b>
Skin	72	0.42	0.011	38.2
Lung	72	4.05	0.011	368.2
Sputum *	15	3.7	0.1	37
Tonsil**	9-18	4.5	0.03	150
	180	0.93	0.006	155
Cervix ***	19	2.8	0.04	70

\* Samples were obtained 2-24 hours after the first dose

\*\* Dosing regimen of 2 doses of 250 mg each, separated by 12 hours

\*\*\* Sample was obtained 19 hours after a single 500 mg dose

The extensive tissue distribution is confirmed by examination of other tissues (prostate; ovary, uterus and salpinx; stomach; liver and gallbladder), in which azithromycin is present in concentrations of 2 mcg/g tissue or greater. However, only very low concentrations are noted in cerebrospinal fluid (less than 0.01 mcg/mL) of noninflamed meninges. High tissue concentrations should not be interpreted to be quantitatively related to clinical efficacy.



When azithromycin oral suspension as the 200 mg/5mL dose was administered with food to 28 adult healthy male subjects, the rate of absorption ( $C_{max}$ ) was increased by 56% while the extent of absorption (AUC) was unchanged.

The extent of absorption is unaffected by co-administration with antacid; however, the  $C_{max}$  is reduced by 24%. Administration of cimetidine (800 mg) two hours prior to azithromycin had no effect on azithromycin absorption. There is no evidence of any pharmacokinetic interaction when azithromycin and theophylline are administered to healthy volunteers.

Azithromycin did not affect the prothrombin time response to a single dose of warfarin (15 mg). However, prudent medical practice dictates careful monitoring of prothrombin time in all patients.

The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02 mcg/mL to 7% at 2 mcg/mL. These values are not likely to be high enough to influence the protein binding of other drugs or to cause significant protein binding interactions with other drugs.

Following a five-day dosing regimen, human bile contains concentrations of azithromycin much greater (approximately 200 mcg/mL) than those in serum (<0.1 mcg/mL), indicating that biliary excretion of azithromycin is a major route of elimination. The major portion of the drug-related material in bile is unchanged drug. Approximately 6% of the administered dose appears in urine. In patients with mild to moderate hepatic impairment, there is no evidence of marked change in serum pharmacokinetics of azithromycin compared to those with normal hepatic function. In these patients urinary recovery of azithromycin appears to increase.

Following oral administration of a single azithromycin 1200 mg dose (two 600 mg tablets); the mean maximum concentration of azithromycin in peripheral leukocytes was 140 ng/mL. Concentrations remained above 32 ng/mL for approximately 60 hr.

The absolute bioavailability of two 600 mg azithromycin tablets was 34%. Administration of two 600 mg tablets with food increased  $C_{max}$  by 31% while the extent of absorption (AUC) was unchanged.

## **MICROBIOLOGY**

### **Mechanism of Resistance**

The two most frequently encountered mechanisms of resistance to macrolides, including azithromycin, are target modification (most often by methylation of 23S rRNA) and active efflux. The occurrence of these resistance mechanisms varies from species to species and, within a species, the frequency of resistance varies by geographical location.

### **Spectrum of Activity**

Azithromycin has been shown to be active against most isolates of the following microorganisms, both *in vitro* and in clinical infections as described in the INDICATIONS SECTION.

**Gram-positive bacteria**

*Staphylococcus aureus*  
*Streptococcus agalactiae*  
*Streptococcus pneumoniae*  
*Streptococcus pyogenes*

**Gram-negative bacteria**

*Haemophilus ducreyi*  
*Haemophilus influenzae*  
*Moraxella catarrhalis* *Neisseria*  
*gonorrhoeae*

**“Other” bacteria**

*Chlamydomphila pneumoniae*  
*Chlamydia trachomatis*  
*Mycoplasma pneumoniae*

The following *in vitro* data are available, but their clinical significance is unknown.

At least 90% of the following bacteria exhibit an *in vitro* minimum inhibitory concentration (MIC) less than or equal to the azithromycin susceptible breakpoint of  $\leq 4$  mcg/mL. However, safety and effectiveness of azithromycin in treating clinical infections due to these bacteria have not been established in adequate and well-controlled trials.

**Gram-positive bacteria**

Beta-hemolytic streptococci (Groups C, F, G)  
Viridans group streptococci

**Gram-negative bacteria**

*Bordetella pertussis*

**Anaerobic bacteria**

*Peptostreptococcus* species  
*Prevotella bivia*

**“Other” bacteria**

*Ureaplasma urealyticum*  
*Legionella pneumophila*  
*Mycoplasma hominis*

Activity of Azithromycin against Mycobacterium avium complex (MAC)

*In vitro* azithromycin has demonstrated activity against Mycobacterium avium complex (MAC) bacteria. Azithromycin has also been shown to be active against phagocytized MAC bacteria in mouse and human macrophage cell cultures.

**Susceptibility Testing Methods**

When available, the results of *in vitro* susceptibility test results for antimicrobial drugs used in

resident hospitals should be provided to the physician as periodic reports which describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports may differ from susceptibility data obtained from outpatient use, but could aid the physician in selecting the most effective antimicrobial.

### Dilution Techniques

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method<sup>54, 52</sup> (broth or agar) or equivalent with standardized inoculum concentration and standardized concentration of azithromycin powder. The MIC values should be interpreted according to criteria provided in Table 1.

### Diffusion Techniques

Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized Procedure<sup>52, 53</sup> requires the use of standardized inoculum concentration. This procedure uses paper disks impregnated with 15-mcg azithromycin to test the susceptibility of bacteria to azithromycin. The disk diffusion interpretive criteria are provided in Table 1.

**Table 1: Susceptibility Interpretive Criteria for Azithromycin  
Susceptibility Test Result Interpretive Criteria**

Pathogen	Minimum Inhibitory Concentrations (mcg/mL)			Disk Diffusion (zone diameters in mm)		
	S	I	R	S	I	R
<i>Haimophilus influenzae</i> <sup>a</sup>	≤ 4	-	-	≥ 12	-	-
<i>Staphylococcus aureus</i>	≤ 2	4	≥ 8	≥ 18	14 - 17	≤ 13
Streptococci including <i>S. pneumoniae</i>	≤ 0.5	1	≥ 2	≥ 18	14 - 17	≤ 13

Susceptibility to azithromycin must be tested in ambient air.

<sup>a</sup> Insufficient information is available to determine Intermediate or Resistant interpretive criteria

The ability to correlate MIC values and plasma drug levels is difficult as azithromycin concentrates in macrophages and tissues.

A report of “susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound reaches the concentrations usually achievable. A report of “intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound reaches the concentrations usually achievable; other therapy should be selected.

## Quality Control

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individual performing the test. Standard azithromycin powder should provide the following range of MIC values noted in Table 2. For the diffusion technique using the azithromycin 15 mcg disks, the criteria in Table 2 should be achieved.

**Table 2: Acceptable Quality Control Ranges for Azithromycin**

QC Strain	Minimum Inhibitory Concentrations (mcg/mL)	Disk Diffusion (zone diameters in mm)
<i>Haemophilus influenzae</i> ATCC* 49247	1.0 – 4.0	13 - 21
<i>Staphylococcus aureus</i> ATCC 29213	0.5 – 2.0	----
<i>Staphylococcus aureus</i> ATCC 25923	----	21 - 26
<i>Streptococcus pneumoniae</i> ATCC 49619	0.06 – 0.25	19 - 25

Susceptibility to azithromycin must be tested in ambient air.

\*ATCC = American Type Culture Collection

## TOXICOLOGY

### Acute Toxicity: Mice and Rats

Oral and Intraperitoneal Toxicity Studies in Mice and Rats			
Route	Species	Sex	LD <sub>50</sub> (mg of free base/kg)
Oral	Mice	M	3000
Oral	Mice	F	4000
Oral	Rats	M	>2000
Oral	Rats	F	>2000
Oral	Neonatal Rats	M	>1000
Oral	Neonatal Rats	F	>1000
I/P	Mice	M	>400 <600
I/P	Mice	F	NA*
I/P	Rats	M	>500

Oral and Intraperitoneal Toxicity Studies in Mice and Rats			
Route	Species	Sex	LD <sub>50</sub> (mg of free base/kg)
			<900
I/P	Rats	F	NA*

\* NA = not available

#### Adult animals (Mice and Rats)

Most mortality occurred within 1 to 2 hours and generally within 48 hours of dosing. At higher doses in mice, symptomatology included clonic convulsive activity, loss of righting reflex, gasping, and blanching prior to death.

Gross necropsy of mice or rats which died following intraperitoneal doses revealed yellowish or clear fluid in the pleural and peritoneal cavities. At necropsy on day 14 there were no gross pathological changes in either species aside from a few liver adhesions to the diaphragm.

#### Neonatal animals (Rats)

No deaths or remarkable clinical signs were observed in any animal during the 14-day observation period. All animals gained weight during the trial. At sacrifice on day 15, no remarkable gross findings were observed in any surviving rat.

#### **Subacute Toxicity**

Phospholipidosis has been observed in animals administered high doses of azithromycin. This effect is reversible after cessation of azithromycin treatment in animals. Despite light- and electron-microscopic correlates of phospholipidosis (myeloid figures and intracytoplasmic vacuoles) in many organs, only in dogs receiving 100 mg/kg/day for at least 2 months have kidney, liver, and gallbladder toxicity been seen. This dose in dogs results in tissue levels greater than 5000 mg/g. Minimal increases in serum transaminase levels in rats and dogs at 20 mg/kg/day and above have also been seen, but are consistent with findings previously reported for erythromycin. Special attention has been given to the effects of phospholipidosis in the retina, including studies of azithromycin, 30 and 100 mg/kg/day for 6 and 2 months, respectively, in dogs. No evidence was elicited of deleterious effects of azithromycin on vision, pupillary reflex or retinal vasculature. The detection of phospholipidosis in the choroid plexus and dorsal root ganglion was not associated with degenerative or functional changes.

## Subacute and Chronic Toxicity

SPECIES	ROUTE	DOSE mg/kg/day	ANIMALS PER DOSE LEVEL	DURATION	FINDINGS
<b>ORAL in Adult Animals</b>					
Rat (Adult)	Oral (gavage)	50 100 200	10/sex	36 days + reversibility	<p>Cecal enlargement was dose-related. Elevated serum hepatic enzyme (SGPT, SGOT, SDH, and 5'NT) levels were dose- and time-related at high and mid-levels; marginal SGPT elevations only were observed in 2 rats at the low dose.</p> <p>Histological examination of tissues from 6/sex of mid- and high-dose and 10/sex of low-dose rats revealed evidence of phospholipidosis in bile ducts (8/20, 12/12, 12/12 low-, mid-, and high-dose rats, respectively) and hepatocytes (10/12 high dose only), fatty change (4/20, 10/12, 11/12 in low-, mid-, and high-doses, respectively), and necrosis of single hepatocytes (6/12 and 11/12, respectively, in mid- and high-dose only). Phospholipidosis also occurred in high-dose rats in the tubular cells of the renal medulla 12/12, spleen 2/12, thymus 2/12, and choroid plexus 10/12; 3/12 rats at 100 mg/kg and 10/12 at 200 mg/kg exhibited mesenteric sinusoidal lymph node phospholipidosis.</p> <p>Phospholipidosis is characterized by accumulation of drug-lipid complexes in lysosomes where they form ultramicroscopic lamellated structures typified at the microscopic level by vacuolated macrophage or tissue cells.</p> <p>The remaining animals (4/sex in control, mid- and high-dose groups) were sacrificed 20 days after termination of treatment. Phospholipidosis was still observable in the renal tubules of 7/8 high dose animals and in 1/8 mid-dose animals and in the bile duct of 1/8 high-dose animals. Fatty change was still detectable in livers of 5/8 and 6/8 mid- and high-dose animals, respectively. Megaceca also regressed following drug withdrawal.</p>
Dog (Adult)	Oral (gavage)	25 50 100	3/sex	36 days	<p>Transaminase levels (SGPT, SGOT) were elevated in a dose-related pattern at the 2 higher doses. ALP (alkaline phosphatase), gamma-GTP, and SDH elevations occurred only at the high dose.</p> <p>Histological examination of tissues revealed the presence of phospholipidosis in all treated animals. It occurred in six or more organs in all 100 mg/kg/day animals. These included kidney, liver, spleen,</p>

SPECIES	ROUTE	DOSE mg/kg/day	ANIMALS PER DOSE LEVEL	DURATION	FINDINGS
					gallbladder, thymus, mesenteric lymph node, esophagus, uterus and cervix as well as lymphatic nodules of gastrointestinal tissues. At the low dose of 25 mg/kg phospholipidosis was confined to the spleen, gallbladder, thymus, mesenteric lymph node and the lymphatic nodules of the ileum and colon.
Rat (Adult)	Oral (gavage)	40 (10 days on 10 days off)  0 continuous 10 " 20 "	15/sex  25/sex	190-193 days + reversibility	Sporadic mild elevations in SGOT and SGPT occurred in all dose groups during and after the treatment period. There was no evidence of phospholipidosis.
Dog (Adult)	Oral (gavage)	40 (10 days on 10 days off)  0 10 20	4/sex  4/sex + 2/sex + 2/sex	190 days  + reversibility 1 month 2 months	Sporadic elevations in SGPT levels occurred at 20 and 40 mg/kg only.  Phospholipidosis, was minimal to mild in the kidney, liver, gallbladder, spleen, mesenteric lymph node, esophagus and prostate of almost all 40 and 20 mg/kg dogs. In dogs dosed for 6 months at 20 mg/kg/day complete reversibility of phospholipidosis of the kidney, liver, and spleen with minimal phospholipidosis still present in the gallbladder and esophagus was demonstrated in the animals sacrificed 2 months after the end of treatment.
Dog (Adult)	Oral (gavage)	30 100	6/sex	6 months  2 months + reversibility	Selected animals were sacrificed at end of treatment; sacrifices (1/sex/dose level) were also performed 1 month (100 mg/kg), 2 months (30 mg/kg) and 4 months (100 mg/kg) post-treatment. Necropsies of the remaining animals were performed 7 months (30 mg/kg) and 11 months (100 mg/kg) post treatment.  Drug treatment of high dose dogs was terminated at 2 months (61 doses) due to intolerance. Serum chemistry changes including substantial increases in liver enzymes (SGPT, SGOT, ALP, SDH, gamma-GPT) and BUN as well as mild decreases in erythrocytic parameters (RBC, Hb, Hct) and the presence of atypical eosinophil and vacuolated lymphocytes returned to normal range within 2 months of withdrawal from treatment. The low dose was well tolerated.

SPECIES	ROUTE	DOSE mg/kg/day	ANIMALS PER DOSE LEVEL	DURATION	FINDINGS
					<p>Dose-related effects on tapetum lucidum reflectivity ranged from trace (low dose) to moderate (high dose) decoloration, dulled reflectivity and loss of the tapetum-choroid junctional zone. Following cessation of treatment, most animals showed improvements in these ocular changes. Normal junctional tissue was evident in high dose animals 4 months after withdrawal. At no time was there ophthalmoscopic evidence of an effect on vision.</p> <p>Histological examination at the end of treatment showed phospholipidosis. In the eye it included the tapetum, neurons of the retinal ganglion cell, inner nuclear, inner and outer plexiform layers, and mural pericytes of the superficial retinal vasculature. The rod and cone segments and retinal pigmented epithelium were generally spared. Also affected were dorsal root ganglion, liver, gallbladder, kidneys, spleen and pancreas and, at the high dose only gastrointestinal tract, mesenteric lymph nodes, thymus, aorta, heart, salivary gland and lung. Dose-related degenerative changes were observed only in the liver (focal necrosis of hepatocytes and bile duct epithelium), gallbladder (hyperplasia) and kidneys (glomerulonephrosis). All of the above effects, with the exception of those on the retina, dorsal root ganglion and gallbladder which all abated in severity, were completely reversible on drug withdrawal from both low and high dose animals. In general, these changes were consistent with the relative drug/tissue concentrations attained and their decline following withdrawal. Biochemical measurements of spleen, liver, kidney and retinal phospholipids of animals treated with 30 mg/kg drug for 6 months showed a difference from control only for the spleen, the tissue with the highest drug concentration.</p> <p>This experiment demonstrates that drug-induced phospholipidosis, although dose-dependent in tissue distribution and intensity, does not represent a toxic end point per se but is responsible for the cumulative tissue deposition of azithromycin.</p>
Dog (Adult)	Oral (gavage)	30 100	6/sex	6 months + reversibility	Intermittent dosing: (10 days on, 10 days off drug) for: 5 months (100 mg), 6 months (30 mg). This experiment demonstrates that intermittent administration (to mimic a hypothetical clinical dose regime) produced less phospholipidosis than azithromycin administered continuously.



SPECIES	ROUTE	DOSE mg/kg/day	ANIMALS PER DOSE LEVEL	DURATION	FINDINGS
<b>ORAL in Neonatal Animals</b> Oral Subacute/Neonatal RATS					
Rat (Neonatal 4 days)	Oral (gavage)	10 20 40	10/sex  10/sex	18 days (day 4 to day 21 postpartum)  10 days (day 4 to day 13 postpartum)	No treatment-related clinical signs were observed. Males given the dose of 20 mg/kg weighed significantly more than the vehicle controls on day 7 and from day 13 to sacrifice on day 22 postpartum. A slight increase in the incidence and prominence of periportal vacuolization appeared treatment related. However, the vacuolization observed in the treated animals was qualitatively no different from that seen in the vehicle-treated controls. There was no histologic evidence of phospholipidosis.
Rat (Neonatal 4 days)	Oral (gavage)	40 60 80	10/sex	18 days (day 4 to day 21 postpartum)	The purpose of this study was to determine the dose at which there was evidence of phospholipidosis. There were no clinical signs of toxicity or effects on body weight.  The administration of azithromycin to neonatal rats by gavage for 18 days produced clear evidence of phospholipidosis of bile duct epithelium in a dose related manner in males and females at all dose levels. Hepatocellular vacuolation, which may also be a manifestation of phospholipidosis, was apparent in most males given azithromycin but was not observed in the vehicle-treated males. However, in the female rats, hepatocellular vacuolation was seen in the azithromycin treated animals as well as in those given the vehicle, suggesting that it does not represent phospholipidosis in this study.
Rat (Neonatal 4 days)	Oral (gavage)	100 120 140	10/sex	18 days (day 4 to day 21 postpartum)	In the previous study, evidence of dose-related phospholipidosis was observed in only the bile duct epithelium of males and females at each dose. The purpose of the present study was to attempt to identify doses at which phospholipidosis is produced in more than one organ and/or tissue.  There were no clinical signs of toxicity.  The administration of azithromycin to neonatal rats by gavage for 18 days produced clear evidence of phospholipidosis of bile duct epithelium in all males and females at each dose. The hepatocellular vacuolation apparent in some animals from each dose was above that seen in the vehicle-treated animals and also appeared to be a manifestation of phospholipidosis. In addition, myocardial

SPECIES	ROUTE	DOSE mg/kg/day	ANIMALS PER DOSE LEVEL	DURATION	FINDINGS
					phospholipidosis was evident in a majority of high and intermediate dose males and females and in a single low dose male.
Rat (Neonatal 4 days)	Oral (gavage)	30 70 140	20/sex 10/sex 10/sex 20/sex	18 days (day 4 to day 21 postpartum)  and  30 Day Reversibility Period for 10/sex in groups treated by 0 and 140 mg/kg.	<p>The purpose of this study was to determine whether phospholipidosis, previously diagnosed by light and electron microscopic examination in neonatal animals treated with azithromycin could be confirmed biochemically by measurement of tissue phospholipid levels.</p> <p>All low and intermediate dose animals, plus one half of the high dose and vehicle-treated control animals were sacrificed on Day 22 postpartum. The remaining rats were sacrificed on Day 52 postpartum after a 30-day reversibility period.</p> <p>Assays for drug in serum, liver and brain samples obtained from pups sacrificed 24 hours after the last dose revealed that the azithromycin concentrations increased with dose and were highest in the liver, lower in the brain and lowest in serum. The concentration of azithromycin in the serum, liver and brain had declined substantially when next measured 31 days after cessation of dosing of the high dose group. Azithromycin was still detectable in the liver and brain, but serum concentrations were generally below the limit of detection. Despite the high azithromycin concentrations detected in both the liver and brain at 24 hours after the last dose, the phospholipid levels in these tissues from rats given azithromycin were no greater than those of the vehicle-treated controls at both the end of the dosing period and after the one month reversibility period.</p> <p>The administration of azithromycin to neonatal Long-Evans rats for 18 days produced light microscopic evidence (vacuolation) of phospholipidosis in bile duct epithelium, hepatocyte cytoplasm, cardiac muscle, smooth muscle of the duodenum and uterus and in the choroid plexus. These changes, seen in the rats sacrificed on the day after the last dose (i.e. Day 22 postpartum), were evident primarily in high dose animals, and, except for the bile ducts, at a much reduced incidence in intermediate dose animals. The only histological evidence of phospholipidosis at the low dose was in the bile ducts of a single male. No light microscopic evidence of phospholipidosis was visible in the high dose animals examined following a 30 day reversibility period.</p>

SPECIES	ROUTE	DOSE mg/kg/day	ANIMALS PER DOSE LEVEL	DURATION	FINDINGS
					It is concluded that, in spite of histological indications of phospholipidosis and high tissue concentrations of azithromycin, there was no biochemical evidence of phospholipid accumulation in affected organs (brain and liver).

Oral Subacute/Neonatal DOGS					
Dog (Neonatal 3-5 days)	Oral (gavage)	10 30 60	3/sex	5 weeks	<p>Pups were removed from their mothers 2 hrs prior to dosing and then returned to their litters immediately thereafter. They were observed daily for developmental landmarks (eye opening, upper canine tooth eruption, ear opening and when pup "leaves the pack"). Body weights were obtained daily. Blood samples for clinical pathology profiles were drawn pretest and prior to dosing on Days 14 and Days 28 or 30. Blood samples for serum drug level determinations were obtained on Days 2, 22 or 24. Ophthalmological examinations were conducted at termination of the treatment period. All dogs were anesthetized and exsanguinated on Days 35 or 37 for necropsy. Selected organs were weighed. Tissues were taken for assays of drug concentrations and for histopathological evaluation.</p> <p>With the exception of a possible lag in body weight gain of female pups, there were no treatment-related effects on developmental landmarks, hematology, clinical chemistry, ophthalmological findings or upon organ weights. Mean blood concentrations of azithromycin, generally related to dose, especially at 10 and 30 mg/kg, were somewhat higher on Day 24 than on Day 2. Evidence of phospholipidosis, previously observed in other azithromycin animal studies, was detected microscopically as swollen vacuolated cells due to myelin figures, i.e. large lysosomes containing aggregates of undigested membranes. As in adult dogs, the dose related phospholipidosis was seen in selected tissues. The effects were minimal to mild at 10 mg/kg. Phospholipidosis was not observed in the brain or in liver. Other dose related lesions were swelling and vacuolation of cells of the tapetum lucidum of the eye due to tapetal rodlet swelling and dissolution, and degeneration and necrosis of epithelial cells lining the gallbladder. The latter occurred only in mid- and high dose animals. Twenty four (24) hrs after the last dose, tissue levels of drug were much higher than in serum with mean concentrations in the order of serum=brain &lt;eye &lt;kidney &lt;liver=spleen.</p>

Dog (Neonatal 3-5 days)	Oral (gavage)	10 30 60	4/sex	11 days	<p>Two/sex/group were necropsied at the end of the dosing period. The remaining animals were maintained for an additional 1 month dose free period prior to being necropsied.</p> <p>There were no treatment-related effects on developmental landmarks, body weight, hematology, clinical chemistry or organ weights. Evidence of phospholipidosis (PL) was observed microscopically at the end of the treatment period in the spleen of dogs given 30 or 60 mg/kg/day and at all dose levels in the neurons of the retina and sympathetic ganglion. The incidence and severity was generally dose related. There was no evidence of PL in the liver or brain. At the end of the 1 month drug free period, the retina and sympathetic ganglion of animals given 10 mg/kg/day had no evidence of PL. PL was still evident, although at a reduced incidence and severity, at dose levels of 30 and 60 mg/kg/day.</p> <p>Following a 1 month drug free period, tissue concentrations of azithromycin in the liver, kidney and spleen were approximately 1.5% of those observed at the end of dosing, indicating elimination of azithromycin from these organs. The extent of elimination from the retina could not be accurately quantitated in this study. However, the reversibility of the PL in the retina would suggest that elimination was occurring.</p>
Dog (Neonatal 3-5 days) and 25 days	Oral (gavage)	10 60	4/sex (3-5 days)  2/sex (25 days)	11 days  and  30 Day Recovery Period	<p>The purpose of this study was to further characterize the absorption and elimination of azithromycin from the choroid/retina of neonatal beagle dogs. At the end of the treatment period, 2/sex from the 3-5 day old dogs and all of the older dogs were necropsied. The remaining dogs were maintained for a 1 month dose free period to further document the elimination of azithromycin from the retina.</p> <p>There were no treatment-related effects on developmental landmarks, body weight, hematology or clinical chemistry. Mean whole blood concentrations of azithromycin were dose related and increased between Days 2 and 11. Liver and choroid/retina of all animals contained dose related concentrations of azithromycin. In general, these were higher in the dogs 3-5 days of age. Concentrations in the choroid/retina were less than those in the previous study (WEL 90-252) and were within historical predictions, while liver concentrations were similar to previous studies and within expectations. At the end of the one month treatment free period, the tissue concentrations of azithromycin had decreased and were within expected levels.</p>

<b>INTRAVENOUS In Adult Animals</b>					
Rat (Adult)	IV	10 20  20 (every other day)	10/sex	14 days	No untoward effects.
Dog (Adult)	IV	10 20  10 (every other day)	3/sex	14 days	No untoward effects with 3 exceptions in the former two groups.  Sporadic elevated serum liver enzyme levels in 2/3 females at the high-dose level; serum alkaline phosphatase levels gradually increased in one 10 mg/kg/day female; phospholipidosis by accumulation of vacuolated macrophages within the lamina propria of the gallbladder and germinal centers of the mesenteric lymph nodes of dogs receiving 20 mg/kg/day.
Rat (Adult)	IV	5 10 20	10/sex	1 month (36-39 days)	Minimal phospholipidosis in the epithelium of the large bile ducts was observed in all high dose and in 13/20 mid-dose animals and at the injection site in the tail of one high dose rat.
Dog (Adult)	IV	5 10 20	3/sex	1 month (36 days)	Slight SGPT elevations occurred in 4/6 high dose animals together with a slight increase in serum alkaline phosphatase activity. Slight SGPT elevations were also noted in 1 low dose and 1 control animal. Histological changes at the high dose were limited to the presence of phospholipidosis. One 10 mg/kg dog also showed minimal phospholipidosis in the large bile ducts. There was no evidence of phospholipidosis at 5 mg/kg/day.
<b>SPECIAL EXPLORATORY TOXICOLOGY</b>					
Rat	Oral (gavage)	10 0 40 200 chloroquin e: 25	5/sex 10/sex  10/sex	5 days	Animals (5/sex/group) from the 40 and 200 mg/kg azithromycin and chloroquine groups were removed from treatment for 23 days to study the effect of reversibility. No elevations in tissue phospholipid levels or hepatic necrosis were seen at any dose. Myelin figures were seen in liver, bile ducts and retinal pigmented epithelium. One chloroquine animal had a few myelin figures in retinal ganglion cells.
Rat	Oral (gavage)	0 200	10/sex	42 days	Phospholipid levels were significantly elevated above control in liver, kidney, spleen and lymphocytes (p<.05).

Dog	Oral (gavage)	0 azithromycin: 10 40 200  chloroquine: 15	1/sex 2/sex  1/sex	5 days	The livers of the 200 mg/kg azithromycin animals showed the highest drug concentration (>4000 mcg/g) of any tissues in the series of experiments. This was accompanied by a 38% elevation in hepatic phospholipids, multifocal hepatic necrosis and marked accumulation of myelin figures in both hepatocytes and bile duct epithelium. Myelin figures were also seen in the liver at 40 mg/kg azithromycin (drug concentration = 817 mcg/g) and with chloroquine but not with 10 mg/kg azithromycin. Azithromycin caused the formation of myelin figures in retinal ganglion cells from equivocal at 10 mg/kg to moderate at 200 mg/kg. The effect was less severe than chloroquine, 15 mg/kg, which caused a marked degree of myelin figure formation in retinal ganglion cells.
Dog	Oral (gavage)	0 azithromycin: 30 erythromycin: 400	1/sex 2/sex  2/sex	5 days	Reversal periods of 22 and 36 days were included for those animals treated with azithromycin (1/sex/period). Tissue phospholipids were elevated in the livers of erythromycin animals only. Myelin figures or enlarged lysosomes were seen to a minimal extent in the retinal ganglion cells, liver and choroid plexus of azithromycin animals and in the liver of erythromycin dogs. The drug concentrations were markedly reduced at the end of the reversal periods and no myelin figures remained in the liver or choroid plexus.
Dog	Oral (gavage)	erythromycin: 400	2/sex	5 days	Dogs were necropsied immediately after the last dose. A few myelin figures were seen in the retinal ganglion cells of one animal.
Dogs Atapetal  Tapetal	Oral	azithromycin:  0 100  0 100	  3 (2M,1F) 3 (2F, 1M)  3 (2M, 1F) 3 (2F, 1M)	35-36 days	Ophthalmoscopic examinations revealed no changes in the atapetal dogs while tapetal decoloration, dulling of normal reflectivity and loss of color difference at the tapetal junctional zone was observed in the tapetal dogs. Light and/or electron microscopic examination of the retinas of both tapetal and atapetal dogs revealed signs of phospholipidosis in ganglion cells, the inner nuclear layer and inner and outer plexiform layers.  Other changes observed in both tapetal and atapetal dogs are comparable to those observed in previous studies at the same dose.

SPECIAL TOXICOLOGY					
Rabbit	IM	0 200 400 (single dose)	3/sex	3 days and 7 days (observation)	Signs indicative of considerable pain upon injection were produced by both volumes of the azithromycin test solution. These changes subsided within 2 to 4 days of dosing. At sacrifice 3 or 7 days post dose, substantial changes were observed in the subcutaneous tissue and the muscle. At 7 days, these changes were much smaller at 1 mL than they were at 2 mL dose.
Rabbit	IV	0 10 (single dose)	3/sex	1 and 2 days (observation)	There were no obvious signs of pain or discomfort upon injection of normal saline with or without azithromycin in the marginal ear vein of six albino rabbits. The gross and microscopic tissue changes indicated that this solution was only minimally irritating.

### Reproductive Studies

SPECIES	ROUTE	DOSE mg/kg/day	ANIMALS PER DOSE LEVEL	DURATION	FINDINGS
<b>FERTILITY AND REPRODUCTIVE PERFORMANCE</b>					
Rat	Oral (gavage)	0 10 20	15M/dose 30F/dose	64-66 days	In females the drug given for 14 days prior to and during cohabitation (1M:2F) and to all females throughout gestation, parturition, and lactation until Day 21 postpartum resulted in a lower pregnancy rate of 63% for the high-dose group compared to 83% and 87% for the low-dose and control groups, respectively.
Rat	Oral (gavage)	30	15M/dose 15F/dose	64-66 days	In females the drug was given 15 days prior to mating and continuously throughout the 3 weeks of mating. A lower pregnancy rate for the drug-treated group (67% compared to 100% in the concurrent control group) was also found here.

<b>FERTILITY EFFECT ON MALES OR FEMALES</b>					
Rat	Oral	0 30	40M/dose 80F/dose (Fertile animals only)	64 days (males)  See text (females)	In females the drug was given 15 days prior to mating and continuously throughout the 3 weeks of mating. Groups were mated as follows:  Group 1: Drug treated males mated with drug treated females. Group 2: Drug treated males mated with control females. Group 3: Control males mated with drug treated females. Group 4: Control males mated with control females.



					<p>Pregnancy rates were: Group 1, 84%; Group 2, 89%; Group 3, 90%; and Group 4, 96%. The pregnancy rate was statistically significantly lower than control when the males and females were both treated with azithromycin (Group 1). The pregnancy rate of 84% in that group was, however, higher than in the two previous studies and well within our historical control range. The nearly identical pregnancy rates in Groups 2 and 3 (89% and 90%, respectively) do not indicate an effect on either sex alone as being the cause for the apparently reduced pregnancy rate.</p>
--	--	--	--	--	---

### **Fetotoxicity Teratology**

<b>SPECIES</b>	<b>ROUTE</b>	<b>DOSE mg/kg/day</b>	<b>ANIMALS PER DOSE LEVEL</b>	<b>DURATION</b>	<b>FINDINGS</b>
Mice	Oral (gavage)	0 10 20 40	20	days 6-13 of gestation	Azithromycin was not toxic to the dams or their fetuses nor was there evidence of teratogenicity.
Mice	Oral (gavage)	0 50 100 200	20	days 6-13 of gestation	Azithromycin was not toxic to the dams or their fetuses nor was there evidence of teratogenicity.
Rat	Oral (gavage)	0 10 20 40	20	days 6-15 of gestation	Azithromycin was not toxic to the dams or to their fetuses nor was there evidence of teratogenicity.
Rat	Oral (gavage)	0 50 100 200	20	days 6-15 of gestation	Azithromycin was not toxic to the dams or fetuses. Dose levels of 100 and 200 mg/kg induced slight delays in maternal body weight gain and in ossification process of fetuses. The compound was neither embryotoxic nor teratogenic at the three dose levels. The 50 mg/kg dose can be considered as the no-observable-effect-level.

PERI/POSTNATAL					
Rat	Oral (gavage)	10 20 40	15	See text	Azithromycin administered from day 15 p.i. through end of gestation and for the whole period of lactation was not toxic to the dams. The pre- and post-natal developments of pups were not affected.
Rat	Oral (gavage)	0 50 100 200	20	See text	Azithromycin administered from day 15 p.i. through end of gestation and for the whole period of lactation was not toxic to the dams. A slight reduction in weight gain of pups and their post-natal development was related to the litter size and not to drug administration. No drug-related external or visceral anomalies were observed.

### Neonatal Studies

SPECIES	ROUTE	DOSE mg/kg/day	ANIMALS PER DOSE LEVEL	DURATION	FINDINGS
Rat	Oral	0 10 20 40	10/sex	18 days (4-21 days postpartum) 10 days (4-13 days postpartum)	There was no evidence of toxicity and no observation of phospholipidosis.
Rat	Oral (gavage)	0 40 60 80	5/sex	18 days (4-21 days postpartum)	Azithromycin induced dose-related microscopic evidence of phospholipidosis only in the bile duct epithelium of both males and females.
Rat	Oral (gavage)	0 100 120 140	5/sex	18 days (4-21 days postpartum)	Azithromycin in addition to affecting the gallbladder epithelium of all animals induced microscopic evidence of myocardial phospholipidosis in a majority of high and intermediate dose pups as well as in a single low dose male. Hepatocellular vacuolation, apparent in some animals at each dose level, more pronounced than that of vehicle treated rats, appeared to be a manifestation of drug-induced phospholipidosis.
Rat	Oral (gavage)	30 70  0 140	10/sex   20/sex	18 days (4-21 days postpartum) + reversibility	Animals (treated and controls) exhibited normal growth and development. All animals at each dose were systemically exposed to azithromycin, as evidenced by the concentration of the compound in the rats' serum, liver and brain at 24 hours after the last dose. At this time point, the concentration of azithromycin in brain and especially liver greatly exceeded that in serum. At 31 days after the last dose, azithromycin is still detectable in the liver and brain of all rats in the high dose (140 mg/kg/day) reversibility

					<p>group, but the serum concentrations were generally below the limit of detection (&lt;0.01 mcg/mL) and the concentration of azithromycin in the liver, brain, and serum was substantially lower than that found one day after the last dose. In spite of the high azithromycin concentrations detected in both the liver and brain at 24 hours after the last dose, the phospholipid levels in these tissues from rats given azithromycin were generally no greater than those of the vehicle-treated controls at both the end of the dosing period and after the one-month reversibility period.</p> <p>In the animals sacrificed the day after the last dose, i.e. on day 22 postpartum, light microscopic evidence of phospholipidosis was apparent in bile duct epithelium, hepatocyte cytoplasm, cardiac muscle, smooth muscle of the duodenum and uterus, and in the choroid plexus. The only evidence of phospholipidosis at the low dose was in the bile ducts of a single male.</p> <p>No light microscopic evidence of phospholipidosis remained in high dose animals examined after a 30-day reversibility period.</p>
--	--	--	--	--	---

### **Carcinogenicity**

Long-term toxicology studies to assess the carcinogenicity potential have not been conducted.

### **Genetic Toxicology**

Azithromycin was examined in several genetic toxicology assays for induction of gene mutations in microbial and mammalian cells and for chromosomal mutations *in vivo* and *in vitro*. No evidence of genotoxic activity was observed in any of the following assays:

**Microbial Assay:** Tests were conducted on strains TA 1535, TA 1537, TA 98 and TA 100 of *Salmonella typhimurium* at concentrations up to 2 mcg/plate (higher concentrations cause bacterial growth inhibition) in the presence and absence of Aroclor-stimulated rat or mouse liver microsomal enzymes. Additional tests were performed using the same strains of *Salmonella* spp. and urine from mice treated orally with up to 200 mg/kg of azithromycin.

**Mammalian Cell Gene Mutation Assay:** The L5178Y Mouse Lymphoma Assay for gene mutations at the thymidine kinase locus was conducted at concentrations of 36-360 mcg/mL to cytotoxicity in the presence and absence of rat liver microsomal enzymes.

**In Vitro Cytogenetics Assay:** The clastogenic activity of azithromycin was evaluated in human lymphocytes *in vitro* exposed up to toxic concentrations of 40 mcg/mL in the presence and 7.5 mcg/mL in the absence of rat liver microsomal enzymes.

***In Vivo* Cytogenetics Assay:** Azithromycin was examined for clastogenic activity in the bone marrow cells of male and female CD-1 mice treated orally at 200 mg/kg, and sacrificed at 6, 24 or 48 hours post-treatment.

### **Antigenicity Studies**

Azithromycin was tested for the induction of a systemic anaphylaxis reaction in guinea pigs and in rabbits. Azithromycin did not have antigenic potential under the conditions used in the studies.

## REFERENCES

1. Arguedas A, Loaiza C, Herrera ML, et al. Comparative trial of 3-day azithromycin versus 10-day amoxicillin/clavulanate potassium in the treatment of children with acute otitis media with effusion. *Int J Antimicrob Agents* 1996;6:233-8.
2. Arguedas A, Loaiza C, Perez A, et al. Microbiology of acute otitis media in Costa Rican children. *Pediatr Infect Dis J* 1998;17(8):680-9.
3. Arguedas A, Loaiza C, Rodriguez F, et al. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion. *J Chemother* 1997;9(1):44-50.
4. Blondeau JM, Suter M, Borsos S et al. Determination of the antimicrobial susceptibilities of Canadian isolates of *haemophilus influenzae*, *streptococcus pneumoniae* and *moraxella catarrhalis*. *J Antimicrob Chemother* 1999;43:25-30
5. Bright GM, Nagel AA, Bordner J, Desai KA, Dibrino JN, Nowakowska J, Vincent L, Watrous RM, Sciavolino FC, English AR, et al. Synthesis, *in vitro* and *in vivo* activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. *J Antibiot (Tokyo)* 1988;41(8):1029-47.
6. Cooper MA, Nye K, Andrews JM, Wise R. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. *J Antimicrob Chemother* 1990;26(4):533-8.
7. Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral Azithromycin and oral Cefaclor in treatment of acute otitis media in infants and young children. *Antimicrob Agents Chemother* 2000;44(1):43-50.
8. Dagan R, Leibovitz E, Greenberg D, et al. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. *Pediatr Infect Dis J* 1998;17(9):776-82.
9. Dagan R, Johnson CE, McLinn S et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. *Pediatr Infect Dis J* 2000;19:95-104
10. Daniel RR. Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children. *J antimicrob Chemother* 1993;31(Suppl E):65-71.
11. Davies BI, Maesen FP, Gubbelmans R. Azithromycin (CP-62,993) in acute exacerbations of chronic bronchitis: an open clinical, microbiological and pharmacokinetic study. *J Antimicrob Chemother* 1989;23(5):743-51.

12. Dunkin KT, Jones S, Howard AJ. The in-vitro activity of CP-62,993 against Haemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci. J Antimicrob Chemother 1988;21(4):405-11.
13. Edelstein PH, Edelstein MAC. *In vitro* activity of azithromycin against clinical isolates of Legionella species. Antimicrob Agents Chemother 1991;35(1):180-1.
14. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl A):73-82.
15. Gary KW, Amsden GW. Intravenous azithromycin. Ann Pharmacotherapy 1999;33:218-228
16. Girard AE, Girard D, English AR, Gootz TD, Cimochoowski CR, Faiella JA, Haskell SL, Retsema JA. Pharmacokinetic and *in vivo* studies with azithromycin (CP- 62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 1987;31(12):1948-54.
17. Girard AE, Girard D, Retsema JA. Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection. J Antimicrob Chemother 1990;25(Suppl A):61-71.
18. Gladue RP, Bright GM, Isaacson RE, Newborg MF. *In vitro* and *in vivo* uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33(3):277-82.
19. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990;34(6):1056-60.
20. Goldstein FW, Emirian MF, Coutrot A, Acar JF. Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae. J Antimicrob Chemother 1990;25(Suppl A):25-8.
21. Hamill J. Multicentre evaluation of azithromycin and penicillin V in the treatment of acute streptococcal pharyngitis and tonsillitis in children. J Antimicrob Chemother 1993;31(Suppl E):89-94.
22. Handsfield HH, Dalu ZA, Martin DH, Douglas JM, McCarty JM, Schlossberg D, and the azithromycin gonorrhoea study group. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhoea. Sex Transm Dis 1994;21(2):107-11.
23. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991;91(Suppl 3A):40S-45S
24. Hopkins S. Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother 1993;31(Suppl E):111-7.

25. Issoire C, Casin I, Perenet F, Brunat N, Janier M, Perol Y, Morel P. Pilot study of azithromycin in the treatment of chancroid caused by *Haemophilus ducreyi*. In: Abstracts of the International Congress for Infectious Diseases. 15-19 July 1990:90. (Abstract #152).
26. Johnson RC, Kodner C, Russell M, Girard D. In-vitro and in-vivo susceptibility of *Borrelia burgdorferi* to azithromycin. *J Antimicrob Chemother* 1990;25(Suppl A):33-8.
27. Jones K, Felmingham D, Ridgway G. *In vitro* activity of azithromycin (CP-62,993), a novel macrolide, against enteric pathogens. *Drugs Exp Clin Res* 1988;14(10):613- 5.
28. Kitzis MD, Goldstein FW, Mieg M, Acar JF. In-vitro activity of azithromycin against various gram-negative bacilli and anaerobic bacteria. *J Antimicrob Chemother* 1990;25(Suppl A):15-8.
29. Manfredi E, Jannuzzi C, Mantero E, Longo L, Schiavone R, Tempesta A, Pavesio D, Pecco P, Chiodo F. Clinical comparative study of azithromycin versus erythromycin in the treatment of acute respiratory tract infections in children. *J Chemother* 1992;4(6):364-70.
30. Martin DH, Sargent S, Wendel GD, Armentor BA, Cammarata CL, Hopkins SJ, Johnson RB. Azithromycin (A) versus ceftriaxone (C) for the treatment of chancroid. In: Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11-14; Anaheim. American Society for Microbiology, 1992:265. (Abstract #931)
31. Maskell JP, Sefton AM, Williams JD. Comparative *in vitro* activity of azithromycin and erythromycin against Gram-positive cocci, *Haemophilus influenzae* and anaerobes. *J Antimicrob Chemother* 1990;25(Suppl A):19-24.
32. Metchock B. In-vitro activity of azithromycin compared with other macrolides and oral antibiotics against *Salmonella typhi*. *J Antimicrob Chemother* 1990;25(Suppl A):29-31.
33. Mohs E, Rodriguez-Solares A, Rivas E, El Hoshy Z. A comparative study of azithromycin and amoxycillin in paediatric patients with acute otitis media. *J Antimicrob Chemother* 1993;31(Suppl E):73-9.
34. Nahata MC, Koranyi KI, Gadgil SD, Hilligos DM, Fouda HG, Gardner MJ. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. *Antimicrob Agents Chemother* 1993;37(2):314-6.
35. Neu HC, Chin NX, Saha G, Labthavikul P. Comparative *in vitro* activity of the new oral macrolide azithromycin. *Eur J Clin Microbiol Infect Dis* 1988;7(4):541-4.
36. O'Doherty B, The Paediatric Azithromycin Study Group. Azithromycin versus Penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. *Eur J Clin Microbiol Infect Dis* 1996;15(9):718-24.
37. Pestalozza G, Cioce C, Facchini M. Azithromycin in upper respiratory tract infections: a clinical trial in children with otitis media. *Scand J Infect Dis* 1992;(Suppl 83):22-5.

38. Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. *Antimicrob Agents Chemother* 2000;44(7):1796-1802.
39. Rapp R. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions. *Ann Pharmacotherapy* 1998;32:785-793.
40. Retsema JA, Girard AE, Girard D, Milisen WB. Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy *in vivo*. *J Antimicrob Chemother* 1990;25(Suppl A):83-9.
41. Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. *Antimicrob Agents Chemother* 1987;31(12):1939-47.
42. Rylander M, Hallander HO. *In vitro* comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide, CP-62,993, against *Mycoplasma pneumoniae*, *Mycoplasma hominis* and *Ureaplasma urealyticum*. *Scand J Infect Dis Suppl* 1988;53:12-7.
43. Schaad UB. Multicentre evaluation of azithromycin in comparison with coamoxiclav for the treatment of acute otitis media in children. *J Antimicrob Chemother* 1993;31(Suppl E):81-8.
44. Schonwald S, Gunjaca M, Kolacny-Babic L, Car V, Gosev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. *J Antimicrob Chemother* 1990;25(Suppl A):123-6. 45.
45. Shepard RM, Falkner FC. Pharmacokinetics of azithromycin in rats and dogs. *J Antimicrob Chemother* 1990;25(Suppl A):49-60.
46. Stamm WE, Workowski K, Hicks CB, Cooper R, Martin DH, Leone PA, Batterger BE, Johnson RB and the Pfizer NGU Study Group. Azithromycin in the treatment of nongonococcal urethritis; a multicenter, double-blind, double-dummy study employing doxycycline as a comparative agent (abstract). In: Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17-20; New Orleans. American Society for Microbiology 1993:120. (Abstract #10)
47. Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Azithromycin in the treatment of sexually transmitted disease. *J Antimicrob Chemother* 1990;25(Suppl A):109-14.
48. Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Single dose azithromycin treatment of gonorrhoea and infections caused by *C. trachomatis* and *U. urealyticum* in men. *Sex Transm Dis* 1994;21(1):43-6.



49. Vergis EN, Indorf A, File TM Jr, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients. *Arch Intern Med* 2000;160:1294-1300.
50. Weippl G. Multicentre comparison of azithromycin versus erythromycin in the treatment of paediatric pharyngitis or tonsillitis caused by group A streptococci. *J Antimicrob Chemother* 1993;31(Suppl E):95-101.
51. Wildfeuer A, Laufen H, Muller-Wening D, Haferkamp O. Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes. *Arzneimittelforschung* 1989;39(7):755-8.
52. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement*. CLSI document M100 S22. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2012.
53. CLSI. *Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - Eleventh Edition*. CLSI document M02-A11. CLSI, Wayne, PA 19087, 2012.
54. Clinical and Laboratory Standards Institute (CLSI). *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Ninth Edition*. CLSI document M07-A9. CLSI 950 West Valley Rd, Suite 250, Wayne, PA 19087, 2012.
55. Product Monograph ZITHROMAX<sup>®</sup>, Pfizer Canada Inc., Control No. 204622, Revision date: July 10, 2017.

**READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE  
PATIENT MEDICATION INFORMATION**

**Pr MYLAN-AZITHROMYCIN**  
Azithromycin Tablets  
USP

**Read this carefully before you start taking MYLAN-AZITHROMYCIN and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about MYLAN-AZITHROMYCIN.**

**What is MYLAN-AZITHROMYCIN used for?**

MYLAN-AZITHROMYCIN is an antibiotic medicine used to treat the following types of **mild to moderate infections by certain microorganisms** in adults such as bronchitis, certain types of skin infections, strep throat (pharyngitis, tonsillitis), genitourinary infections, disseminated mycobacterium avium complex (MAC) disease in people with HIV, and pneumonia.

Antibacterial drugs like MYLAN-AZITHROMYCIN treat only bacterial infections. They do not treat viral infections such as the common cold. Although you may feel better early in treatment, MYLAN-AZITHROMYCIN should be taken exactly as directed. Misuse or overuse of MYLAN-AZITHROMYCIN could lead to the growth of bacteria that will not be killed by MYLAN-AZITHROMYCIN (resistance). This means that MYLAN-AZITHROMYCIN may not work for you in the future. Do not share your medicine.

**How does MYLAN-AZITHROMYCIN work?**

MYLAN-AZITHROMYCIN helps stop the growth of the bacteria that cause infection. It gets into infected tissue where it is released slowly over time so the medicine keeps fighting bacteria for many days after the last dose is taken. This is why MYLAN-AZITHROMYCIN may be taken for as short a time as one day.

**What are the ingredients in MYLAN-AZITHROMYCIN?**

Medicinal ingredient: Azithromycin dihydrate

Non-medicinal ingredients:

250 mg tablets: Croscarmellose sodium D&C Red No. 27, FD&C Blue No. 2, FD&C Red No. 40, FD&C Yellow No.6, Hydroxypropylmethyl Cellulose, Lactose, Magnesium Stearate, Poloxamer 188, Povidone, Silicified Microcrystalline Cellulose, Polyethylene Glycol, Talc and Titanium Dioxide.

**MYLAN-AZITHROMYCIN comes in the following dosage forms:**

Tablets: 250 mg.

**Do not use MYLAN-AZITHROMYCIN if you:**

- have a history of liver problems when you have used azithromycin.

- are hypersensitive (allergic) to azithromycin, or any macrolide or ketolide antibiotic (including erythromycin) or any other ingredient of MYLAN-AZITHROMYCIN (see What are the ingredients in MYLAN-AZITHROMYCIN).

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take MYLAN-AZITHROMYCIN. Talk about any health conditions or problems you may have, including if you:**

- have a known prolonged heart cycle (interval) (QT prolongation)
- are currently taking medication known to prolong QT interval (prolong your heart cycle) such as antiarrhythmics (drugs to regulate your heart beat such as class IA: quinidine, procainamide and class III; dofetilide, amiodarone, sotalol); antipsychotic agents; antidepressants; and fluoroquinolones (a class of antibiotics)
- have a history of life-threatening irregular heart beat
- have constantly low levels of potassium or magnesium in your blood
- have a history for heart problems such as slow heart rate, irregular heart beat or cardiac insufficiency (your heart has a hard time pumping blood to your body)
- are pregnant or think you are pregnant,
- are breast feeding or planning to breastfeed. Azithromycin has been reported to be excreted in human breast milk. It is not known if MYLAN-AZITHROMYCIN could affect your baby. Discuss with your doctor.
- have ever had any liver or kidney problems
- have a weak immune system
- have ever had an allergic reaction to any medicines, including antibiotics such as erythromycin
- have myasthenia gravis (a chronic autoimmune neuromuscular disease which causes muscle weakness)
- have hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption as this product contains lactose.

**Other warnings you should know about:**

You should begin to feel better within the first few days, but be sure to take MYLAN-AZITHROMYCIN for the full number of days your doctor prescribed. Although MYLAN-AZITHROMYCIN dosing is short, you should not expect MYLAN-AZITHROMYCIN to work faster than other antibiotics which are dosed up to 10 days. If you stop taking MYLAN-AZITHROMYCIN too soon, your infection could come back. The next infection may be worse and be more difficult to treat. If you are not able to take all the medicine, tell your doctor.

If you develop diarrhea during or after treatment with MYLAN-AZITHROMYCIN, tell your doctor at once. Do not use any medicine to treat your diarrhea without first checking with your doctor.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with MYLAN-AZITHROMYCIN:**

- Warfarin (or other anticoagulant medicine);
- Cyclosporin (used to suppress the immune system to prevent and treat rejection in organ or bone marrow transplants);
- Digoxin (used for treatment of heart problem);
- Nelfinavir (used for treatment of HIV infections);
  - Ergotamine and ergot derivatives (used for migraine treatment). Ergotamine and ergot derivatives should not be used with MYLAN-AZITHROMYCIN.

Some medicines may affect how well MYLAN-AZITHROMYCIN works. Check with your doctor before starting any new prescription or over-the-counter medicines, including natural/herbal remedies or antacids, while on MYLAN-AZITHROMYCIN.

**How to take MYLAN-AZITHROMYCIN:**

Always take MYLAN-AZITHROMYCIN as the doctor has prescribed for you, depending on the specific condition you have.

MYLAN-AZITHROMYCIN can be taken with or without food.

**Usual adult dose:**

If your doctor prescribes MYLAN-AZITHROMYCIN 250 mg tablets for 3 days for treatment of bronchitis:

Days 1 through 3: Take two tablets each day.

If your doctor prescribes the 5 day MYLAN-AZITHROMYCIN 250 mg tablets for 5 days for treatment of respiratory tract infections or certain types of skin infections:

Day 1: Take 2 tablets once.

Day 2 through 5: Take 1 tablet daily.

If your doctor prescribes MYLAN-AZITHROMYCIN 250 mg tablets for 1 day for treatment of genital ulcers or non-gonococcal urethritis and cervicitis:

Days 1: Take four tablets once.

If your doctor prescribes MYLAN-AZITHROMYCIN 250 mg tablets for 1 day for treatment of gonococcal urethritis and cervicitis:

Days 1: Take eight tablets once.

**Overdose:**

If you think you have taken too much MYLAN-AZITHROMYCIN, contact your healthcare professional, hospital emergency department or regional Poison Control Center immediately, even if there are no symptoms.

**Missed Dose:**

If you forget to take a dose, call your pharmacist or doctor. Do not double dose.

**What are possible side effects from using MYLAN-AZITHROMYCIN?**

These are not all the possible side effects you may feel when taking **MYLAN-AZITHROMYCIN**.

If you experience any side effects not listed here, contact your healthcare professional.

Side effects may include:

- Diarrhea/loose stools
- Stomach pain
- Nausea and vomiting
- Headache

<b>Serious side effects and what to do about them</b>			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<b>COMMON</b> <b>Clostridium difficile colitis (bowel inflammation):</b> severe diarrhea (bloody or watery) with or without fever, abdominal pain, or tenderness			√
<b>UNCOMMON</b> <b>Abnormal heart rhythm:</b> feel your heart beating in your chest, abnormal heartbeat, dizziness or feeling faint			√
<b>Severe allergic reaction:</b> trouble breathing, swelling of the face, mouth, throat, neck, severe skin rash or blisters			√
<b>Liver disorder:</b> abdominal pain, nausea, vomiting, yellowing of skin and eyes, dark urine			√
<b>Myasthenia gravis:</b> muscle weakness, drooping eyelid, vision changes, difficulty chewing and swallowing, trouble breathing		√	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

### **Reporting Side Effects**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### **Storage:**

Store MYLAN-AZITHROMYCIN at controlled temperature between 15°C and 30°C

Keep MYLAN-AZITHROMYCIN and all medicines out of the reach and sight of children.

### **If you want more information about MYLAN-AZITHROMYCIN:**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>); the manufacturer's website or by calling 1-844-596-9526.

This leaflet was prepared by Mylan Pharmaceuticals ULC.

Last Revised: February 8, 2018